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ABSTRACT 
 
 
Mantle Cell Lymphoma (MCL) is a rare but aggressive Non-Hodgkin Lymphoma (NHL). Although 
t(11;14) is a hallmark of MCL, it is insufficient for lymphomagenesis. The phosphoinositide-3 kinase 
(PI3K) pathway is thought to play an important role in MCL pathogenesis and the PI3K p110δ isoform 
is enriched in leucocytes making it an attractive target. Early phase trials evaluating the p110δ 
selective inhibitor GS-1101 however demonstrate inferior responses in MCL compared to chronic 
lymphocytic leukaemia and indolent NHL.  
 
The relative contribution of the class Ia PI3K isoforms p110α (PIK3CA), p110β (PIK3CB) and p110δ 
(PIK3CD) was therefore evaluated in MCL. Immunohistochemistry on MCL tissue microarrays 
revealed that while p110δ was highly expressed, p110α showed wide variation and p110β 
expression was the weakest. A significant increase in p110α expression was found with disease 
progression. Although GS-1101 was sufficient to abolish B-cell receptor mediated PI3K activation, 
additional p110α inhibition was necessary to abolish constitutive PI3K activation in MCL exhibiting 
high p110α expression. Compared to GS-1101, GDC-0941 (p110α and p110δ inhibitor) had greater in 
vitro toxicity and a high PIK3CA/PIK3CD mRNA ratio (> twice ratio in healthy B-cells) was able to 
identify primary MCL samples that were resistant to GS-1101 but significantly more sensitive to 
GDC—0941. This ratio also increased with disease progression. No PIK3CA or PIK3R1 activating 
mutations were found. In summary, blockade of both p110α and p110δ appears to be necessary for 
effective PI3K inhibition in MCL, particularly with relapse. The PIK3CA/PIK3CD mRNA ratio may help 
identify those patients that are most likely to respond.  
 
Finally, a disseminated xenograft model of human primary MCL was established in NSG mice. 
Engraftment of primary MCL was demonstrated by peripheral blood flow cytometry, tissue 
immunohistochemistry and FISH for t(11;14). This model is potentially valuable for pre-clinical in vivo 
testing of novel drugs for this incurable disease. 
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CHAPTER 1: INTRODUCTION 
 
1.1 MANTLE CELL LYMPHOMA 
 
1.1.1 Introduction 
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) that was first recognised as a 
distinct entity in 1994,1 although the concept of a ’mantle zone lymphoma’ was introduced by 
Weisenburger et al as far back as 1982.2 MCL is relatively rare and constitutes about 2-10% of all NHL 
with an incidence of approximately 0.5 per 100,000 in the western world.3 The majority of patients 
are elderly males with a median age of approximately 70 years at diagnosis and a male to female 
ratio of 2-3:1 (Figure 1.1). Advanced stage disease with bone marrow and extranodal involvement, 
particularly of the gastrointestinal tract, where it is often seen as multiple lymphomatous polyps, is 
frequently found and approximately a third of all patients present with lymphocytosis in the 
peripheral blood. Central nervous system involvement is not uncommon in MCL and is more 
frequent with blastoid morphology and advanced disease.4,5  
 
Figure 1.1 Estimated age-specific incidence of Mantle Cell Lymphoma in the United Kingdom 
 
Source: www.hmrn.org 
16 
 
Although there has been an improvement in overall survival from the 2-4 year range cited in earlier 
series to between 5 and 7 years in more recent studies,6 MCL remains incurable with conventional 
treatment. Apart from better supportive care, improvement in overall survival of patients is 
attributable to aggressive treatment of younger and/or fitter patients with high dose cytarabine 
containing regimens, such as hyperCVAD and maxiCHOP/Ara-C, as well as the use of autologous and 
allogeneic stem-cell transplantation, all of which are associated with significant toxicity and can 
adversely impact on quality of life. The Kaplan-Meier curve in figure 1.2, derived from the overall 
survival of 120 patients with MCL treated at Barts between 1975 and 2010, emphasises the need for 
improved management of this condition. 
 
In recent years, a better understanding of the genetic and molecular basis of MCL has revealed a 
number of promising targets, including the phosphoinositide-3 kinase (PI3K) pathway. Given the 
relative rarity of MCL, pre-clinical evaluation of these drugs in parallel with biomarker discovery is 
essential for effective targeting of this aggressive and incurable neoplasm.  
 
Figure 1.2 Kaplan-Meier survival estimate for patients treated at Barts hospital between 1975 and 
2010 (N=120) 
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1.1.2 Genetic and molecular basis 
MCL likely originates from B-cells of the inner mantle zone of secondary lymphoid follicles. The cell 
of origin in MCL is not restricted to the naive pre-germinal centre B-cell as previously thought and 15 
- 40% of cases are found to have hypermutated immunoglobulin heavy chain variable region (IGHV) 
genes.7-10 Morphologically, MCL consists of small to medium sized lymphocytes with irregular 
nuclear contours in the majority of cases. Although a number of morphological variants have been 
described, only the small cell (classical) and blastoid variants are of potential clinical significance. 
Blastoid morphology, which is found in about 20% of patients at presentation, can be recognised by 
an increase in nuclear size and chromatin dispersal along with prominent nucleoli and pleomorphism 
in some cases (Figure 1.3). The risk of transformation to blastoid MCL for those presenting with small 
cell morphology is approximately 42% over 5 years.11 MCL cells exhibit a mature B-cell phenotype 
with expression of CD19, CD20, CD22 and CD79a. CD5 is co-expressed in the majority of cases but, in 
contrast to chronic lymphocytic leukaemia (CLL), CD20 expression is strong, FMC7 is expressed and 
CD23 is usually absent. The germinal centre markers CD10 and BCL6 are absent.12  
 
Figure 1.3 Classical and blastoid morphological variants in MCL 
 
 
The diagnostic hallmark and primary event in MCL pathogenesis is t(11;14) which results in fusion of  
the immunoglobulin heavy chain (IGH) promoter at 14q32 to the gene encoding cyclin D1 (CCND1), 
at 11q13, leading to the characteristic over-expression of cyclin D1.13 Approximately 6% of MCLs are 
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negative for this translocation but are found to over-express cyclin D2, D3 or E.14 This primary event 
leads to deregulation of the cell cycle at the G1/S phase transition but is unlikely to be sufficient for 
MCL tumorigenesis as suggested by observations that Eµ-cyclin D1 transgenic mice fail to develop 
tumours spontaneously. However, exposing these mice to a mitogenic stimulus (isoprane) over a 
period of time, leads to development of a CD20 and cyclin D1 expressing MCL-like lymphoma 
involving the spleen, bone marrow and lymph nodes.15 Similarly double transgenic mice with Eμ-
linked co-expression of cyclin D1 and MYC develop spontaneous lymphomas implying secondary hits 
are necessary for mantle cell lymphomagenesis.16 
 
A number of secondary genetic events have now been described in MCL, consisting of recurrent 
copy number amplifications and chromosomal gains and losses. These events primarily converge on 
pathways involving the cell cycle and DNA damage response.17 Deletions involving the INK4a/ARF 
locus and mutations involving TP53 and the PI3K domain of the DNA damage response gene ATM 
(found in 40-75% of cases) are some common examples.18,19 MCL therefore shows high genetic 
instability with more complex karyotypes often associated with blastoid morphology20 and 
aggressive behaviour. In addition to genetic aberrations, both gene expression profiling and 
proteomic studies have implicated the PI3K/Akt/mTOR,21-24, NFκB25 and WNT21,26 signalling pathways 
in proliferation and survival of MCL. More recently, whole transcriptome sequencing has revealed 
recurrent mutations in NOTCH1, primarily involving the PEST domain, with a frequency of 12%. In 
the same study NOTCH inhibition with a gamma-secretase inhibitor was shown to inhibit growth and 
induce apoptosis in two MCL cell lines.27  
 
Studies of the microenvironment in MCL are few compared to other lymphomas but interaction with 
the surrounding cellular and chemical components almost certainly plays an important role in 
conjunction with signalling pathways in the survival of neoplastic cells. MCL carrying hypermutated 
IGHV genes show a strong bias in the IGHV gene repertoire and therefore, similar to CLL, antigen 
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selection may be an important driver of clonal expansion.10  Reports of constitutive SYK activation 
and the identification of SYK and BTK among the most abundant phosphoproteins in a recent 
phosphoproteomic study further emphasize the importance of B-cell receptor (BCR) signalling in 
MCL.24,28 In addition, tumour cells have been found to express high levels of CXCR4, CXCR5 and VLA-4 
and have been observed to proliferate in response to CD40 ligand as well as interleukin-4 (IL4) 
stimulation in vitro.29 Furthermore, a chemo-protective role for mesenchymal stromal cells has been 
demonstrated in co-culture studies with MCL cells.30 More recently, autocrine and paracrine 
secretion of IL-6 has been reported to be key to MCL survival through activation of the PI3K/Akt and 
JAK-STAT pathways.31 The role of T-cells and macrophages in MCL is less clear. In one study a 
macrophage infiltration (CD68+ cells) of greater than 5% was reported as being associated with a 
significantly worse overall survival but, similar to observations in follicular lymphoma, the 
significance of this finding was lost in rituximab treated patients.32  
 
1.1.3 Prognostic markers 
MCL is an aggressive neoplasm in the vast majority of patients. However, in a small minority this 
lymphoma behaves indolently and can even be managed expectantly with no detrimental effects on 
survival.33,34 A number of studies have analysed clinical and molecular characteristics that may 
predict for indolent disease. It is now becoming clear that most patients with indolent MCL present 
with isolated leukaemic (non-nodal) disease whereas patients with nodal disease are more likely to 
have more aggressive lymphoma.35,36 Molecular markers such as SOX11,37,38 IGHV mutation status39-
41 and 17p deletions/TP53 mutations 42,43 continue to be controversial as independent prognostic 
markers, but may have a better predictive value when evaluated in conjunction with clinical 
characteristics. For example, nodal MCL with unmutated or minimally mutated IGHV and positive 
SOX11 is very likely to have a significantly worse prognosis than isolated leukaemic disease with 
mutated IGHV, negative SOX11 and a wild type TP53. Leukaemic disease with mutated TP53, on the 
other hand, is more likely to follow an aggressive clinical course.44,45 A recent study of somatic 
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hypermutation in MCL evaluated a >97% homology cut-off, as opposed to the 98% cut-off used in 
CLL studies, for differentiating IGHV mutated from unmutated MCL and demonstrated that this was 
able to clearly define a unmutated/minimally mutated cohort with a significantly worse prognosis.45 
Nevertheless, a combination of these clinical and molecular characteristics is likely to be superior for 
defining indolent disease than any single marker.  
 
The Ki-67 tumour proliferation fraction, MIPI (MCL international prognostic index) and minimal 
residual disease (MRD) analysis are three well established independent prognostic markers that 
have a strong predictive value in MCL. Using gene expression profiling, the Leukemia Lymphoma 
Molecular Profiling group demonstrated that a signature of proliferation genes was able to identify 
MCL subsets differing in median survival by over 5 years.46 This led to the evaluation of Ki-67, a non-
histone nuclear protein found exclusively in proliferating cells, as a prognostic marker using 
immunohistochemistry. The percentage Ki67-positivity has now been shown to be highly predictive 
of outcome in multivariate analysis and retains its validity in the rituximab era47-49 (Table 1.1). 
Consensus guidelines have been published recently on the use of Ki-67 as a marker of proliferation 
in MCL.50  
 
The MIPI was formulated by the European MCL network following data evaluation from over 450 
patients with advanced stage MCL treated in 3 clinical trials and incorporates patient age, ECOG 
status, LDH and white cell count to provide a predictive score.51 Patients can be divided into three 
distinct categories with significantly different survival based on this score. A simplified MIPI and a 
‘biological MIPI’ (incorporating the Ki-67 index) have also been described and are detailed in table 
1.2. Another important independent prognostic marker is PCR based sequential minimal residual 
disease (MRD) monitoring. In two large MCL clinical trials, significantly improved response duration 
was seen in patients who achieved molecular remission independent of the degree of clinical 
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remission (CR, CRu or PR).52 The predictive value of MRD monitoring has recently been confirmed in 
an independent study by the Cancer and Leukemia Group B (CALGB).53 
 
Table 1.1 Prognostic value of Ki67 proliferation index  
Ki67 proliferation index  Median survival  
<10% 
11-40 
>40% 
42 months 
30 months 
15 months 
Tiemann et al 200549 
 
Table 1.2 Mantle cell lymphoma international prognostic index (MIPI)
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Other prognostic markers that have been described in MCL include the five-gene model (RAN, MYC, 
TNFRSF10B, POLE2, and SLC29A2)54 and more recently, methylation profiles,55 NOTCH mutations,27 
microRNA signatures56 and serum free light chain ratios.57 These will need further validation, but 
have contributed to our understanding of this biologically complex disease. 
 
1.1.4 Current management 
Until recently patients with MCL were treated heterogeneously with treatments ranging from 
expectant management to a variety of chemotherapy regimens and stem cell transplant. In the last 
10 years, collaborative efforts like the European MCL network have been able to provide evidence-
based recommendations to guide first-line treatment through large clinical trials. The treatment of 
relapsed disease remains a difficult challenge but the number of novel agents with proven clinical 
efficacy has grown rapidly in the last few years and has created an exciting platform for future 
studies.  
 
As discussed briefly in the previous section, patients with asymptomatic MCL can be managed 
expectantly with no detrimental effect on survival. While Martin et al demonstrated a significant 
survival advantage in those patients in whom treatment was deferred,34 Eve et al did not find any 
significant difference between these two approaches in an independent cohort33 suggesting that a 
watch and wait approach is at least non-inferior in these patients, as long as they are closely 
monitored for progression.  
 
Over 90% of patients with MCL present with stage III or IV (modified Ann-Arbor) disease but in the 
small proportion who present with limited stage disease, radiotherapy with or without 
chemotherapy may be indicated. There is good evidence that MCL is radiosensitive and localised 
disease can be treated with involved field radiotherapy to satisfactory responses that are, in some 
cases, sustained for several years.58-60  
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A handful of studies, particularly the recently reported National Cancer Research Institute (NCRI) 
phase III  study comparing FC (fludarabine, cyclophosphamide) and R-FC,61 have provided evidence 
for improved response rates and progression free survival (PFS) with the addition of rituximab to 
chemotherapy in front line treatment of MCL.62-64 In younger, fitter patients it is now widely 
accepted that a chemotherapy regimen containing high dose Ara-C, such as R+maxiCHOP/Ara-C or R-
DHAP (dexamethasone, cytarabine, cisplatin), followed by autologous stem cell transplant (ASCT) is 
likely to provide the most benefit in terms of PFS. This significant prolongation of PFS with upfront 
ASCT was first demonstrated by Dreyling et al in the landmark first randomised study of the 
European MCL network.65 Subsequently the Nordic lymphoma group MCL 2 study showed there was 
a significant improvement in response rates and PFS from addition of high dose Ara-C and rituximab 
to the maxiCHOP induction, compared to the same group’s previous MCL1 study of maxiCHOP and 
BEAM ASCT.66 The benefit of high dose Ara-C in significantly improving response rates, time to 
treatment failure and, for the first time, overall survival (OS) was recently reported at the 2012 ASH 
annual meeting in the final analysis of the European MCL network randomised study (MCL younger 
trial) that compared 6 cycles of R-CHOP to alternating cycles of R-DHAP (x3) and R-CHOP (x3) 
followed by  ASCT.67 Another very active regimen is R-hyperCVAD/Ara-C and methotrexate that has 
been shown to achieve high response rates in younger patients without the need for ASCT but the 
significant toxicities associated with this regimen have discouraged more widespread use.68,69 Table 
1.3 summarises selected regimens from clinical trials that have achieved high response rates and 
progression free survival. 
 
The treatment of elderly patients is guided by performance status and co-morbidities, and a number 
of chemo-immunotherapy options such as R-FC, R-CHOP, R-CVP, R-bendamustine and R-
chlorambucil have been evaluated. Although R-CHOP is often included in the standard arm in 
randomised trials there is no evidence for benefit with addition of anthracycline and R-CVP may be 
equally effective.70,71 A recent landmark study for the treatment of elderly patients with MCL (>60 
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years and not eligible for high dose therapy, median age 70 years) was reported by the European 
MCL network72 providing evidence in favour of R-CHOP followed by rituximab maintenance for front-
line treatment in this cohort. This trial evaluated an initial induction randomisation between R-CHOP 
and R-FC followed, in responding patients, by a maintenance randomisation between rituximab and 
interferon alpha (given until progression). Patients who received R-CHOP induction had a 
significantly better OS and PFS compared to R-FC while rituximab maintenance significantly reduced 
the risk of progression or death compared to interferon alpha maintenance. 
 
Relapsed MCL has a dismal prognosis with a median survival of 1-2 years. There is evidence for graft-
versus-lymphoma effect in MCL and reduced intensity conditioning allogeneic stem cell 
transplantation (AlloSCT) has a role in eligible patients who have an appropriate donor and chemo-
sensitive disease.73,74. Myeloablative conditioning regimens have high treatment related mortality 
(30-40%) and experience with AlloSCT in refractory disease is limited.  In patients not eligible for 
AlloSCT, in addition to the use of another standard regimen to which the patient has not previously 
been exposed, a number of alternative chemotherapy regimens have been evaluated with varying 
efficacy.  These include cladiribine,75 R-FCM (additional mitoxantrone),76 PEP-C (prednisone, 
etoposide, procarbazine, cyclophosphamide),77 temsirolimus,78 bortezomib79,80 and 
gemcitabine/dexamethasone/cisplatin.81 Clinical trial data for these regimens along with some of the 
promising newer agents that have significant activity in relapsed/refractory MCL are summarised in 
table 1.4. The activity of PI3K pathway inhibitors in MCL is discussed in greater detail in section 1.3. 
Other novel inhibitors including Flavopiridol (pan cyclin-dependent kinase inhibitor), Enzastausrin 
(PKCβ inhibitor) and Fostamatinib (SYK inhibitor) have shown disappointing activity in MCL despite 
the potential importance of their targets in MCL pathogenesis.  
 
In summary, while there has been a significant improvement in our understanding of how to use 
conventional chemotherapy in frontline treatment to improve responses and outcomes in MCL, 
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further improvements are only likely to come from a better understanding of which novel therapies 
to use and also how and when to use them. A number of these therapies have already shown great 
promise in early phase trials with significant prolongation of progression free survival and very 
favourable toxicity profiles,. The challenge now lies with effectively evaluating this armamentarium 
of novel therapies in a rare lymphoma like MCL but this can potentially be overcome with increased 
emphasis on models for pre-clinical evaluation and biomarker discovery. 
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Table 1.3 Selected data from clinical trials in front-line MCL showing the best progression-free and overall survival rates achieved with current chemo-
immunotherapy and dose-intense regimens 
 
Regimen N 
ORR 
(CR/Cru) 
Median PFS 
(months) 
Median OS 
(months) 
Reference 
 
Immuno-chemotherapy 
regimens 
R-Chlorambucil 14 64% (36%) 26 - Bauwens et al 2005 
R-CHOP 62 94% (34%) 20 Not reached Lenz et al 2005 
R-FC 186 91% (65%) 31 - Rule et al 2011 
R-CHOP / R maintenance 87 86% (34%) 
With induction 
Not reached 87% at 48mths Kluin-Nelemans et al 2012 
 
 
 
 
Dose-intense regimens 
HyperCVAD / high dose 
methotrexate + Ara-C 
45 93.5% (38%) 72% at 36mths 92% at 36mths Khouri et al 1998 
MaxiCHOP / high dose  
Ara-C / ASCT 
160 90% CR 56% at 72mths 75% at 48mths Geisler et al 2008 
R-HyperCVAD / high dose 
methotrexate + Ara-C 
97 97% (87%) 4.6 yrs Not reached Romaguera et al 2010 
R-HyperCVAD / high dose 
methotrexate + Ara-C 
60 83% (72%) 61% at 5yrs 
(estimated) 
73% at 5 yrs 
(estimated) 
Merli et al 2012 
R-CHOP / ASCT 
 
R-DHAP / R-CHOP / ASCT 
 
455 
 
90% (40%) 
 
95% (54%) 
49 
 
84 
82mths 
 
Not reached 
 
Hermine et al 2012 
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Table 1.4 Selected clinical trial data with conventional regimens and novel therapies in relapsed/refractory MCL 
Therapy N ORR 
(CR/Cru) 
Median PFS 
(months) 
Median OS 
(months) 
Median lines of 
previous therapy 
Reference 
Purine analogues 
 
R-FC 
R-FCM 
Cladiribine 
16 
24 
25 
75% 
58% (29%) 
46% (21%) 
11 
8 
5.4 
- 
Not reached 
22.8 
2(1-6) 
1 
- 
Thomas et al 2005 
Forstpointner et al 2004 
Inwards et al 2008 
Other cytotoxics 
 
Gemcitabine-dexamethasone-cisplatin 
R-bendamustine 
PEP-C 
18 
16 
22 
44.4% (9%) 
75% (50%) 
82% (46%) 
8.5 
18 
- 
Not reached 
- 
- 
1 (1-3) 
1 (1-3) 
- 
Morschhauser et al 2007 
Rummel et al 2005 
Coleman 2008 
Proteasome 
inhibitor 
 
Bortezomib 
Bortezomib-gemcitabine 
R-Bortezomib 
155 
26 
19 
32% (8%) 
58% (12%) 
58% (16%) 
6.7 
11.4 
- 
23.5 
- 
- 
2 (1-3) 
1 (1-3) 
- 
Goy et al 2009 
Kouroukis et al 2011 
Agathocleous et al 2010 
mTOR inhibitor 
 
Temsirolimus 
R-Temsirolimus 
35 
69 
38% (3%) 
59% (19%) 
6.5 
9.7 
12 
29.5 
3 (1-11) 
2 (1-9) 
Witzig et al 2005 
Ansell et al 2011 
Immunomodulatory 
agents 
R-Thalidomide 
Lenalidomide 
16 
57 
81% (31%) 
24% (12%) 
20.4 
5.7 
Not reached 
- 
1 
3 
Kaufmann et al 2004 
Witzig et al 2011 
PI3K inhibitor GS-1101  21 48% 4 - 5 (1-12) Kahl et al 2010 
BTK inhibitor Ibrutinib 109 66% (19%) Not reached Not reached 3 (1-6) Wang et al 2012 
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1.2 THE PHOSPHOINOSITIDE-3 KINASE PATHWAY 
 
1.2.1 Introduction 
The term phosphoinositide-3 kinase (PI3K) refers to lipid kinases that can phosphorylate the 3-
hydroxyl position of the inositol ring of the phosphatidylinositol membrane lipids (PtdIns). PI3Ks and 
the 3-phosphoinositides they generated were first discovered in the late 1980s in studies examining 
the transformation of 3T3 fibroblasts by the polyoma virus middle T (PMT) antigen.82,83 The 
observation that association of PMT with PI3K correlated with transformation and that PMT mutants 
that failed to associate with PI3K did not result in transformation, indicated an essential role for this 
enzyme in the transformation process.84 Until this discovery, the existence of 3-OH phosphorylated 
PtdIns was not known and interest in PtdIns had focussed on receptor-stimulated hydrolysis of 
phosphoinositide (3,4) biphosphate (PIP2) by phospholipase C (PLC) leading to inositol (1,4,5) 
triphosphate (IP3) and diacylglycerol (DAG)
85 production. The discovery of this new class of enzymes 
and the 3-phosphoinositides they generated [PI86 monophosphate, PI(3,4) diphosphate and PI(3,4,5) 
triphosphate] placed PI3Ks in a new pathway, now known as the PI3K signalling pathway, distinct 
from PLC-dependent signalling. Further milestones in PI3K research led to better understanding of 
the heterodimeric structure and isoforms of the enzyme,87-93 mechanisms of regulation,94-97 
downstream targets98-102 and its role in healthy and malignant cells.103-107 Some of these milestones, 
including the development of mutant/knockout mouse models108-113 and pharmacological 
inhibitors,114-117  which have been central in establishing a better understanding of this pathway, are 
detailed in the timeline in figure 1.4. This timeline is not exhaustive, but it provides a snapshot of the 
transition from basic science discoveries to bedside applications in the field of PI3K research. PI3Ks 
are part of a complex signalling network with multiple inputs and downstream effects and our 
knowledge of this pathway is far from complete, but the entry of PI3K inhibitors into the clinic and 
the impressive single agent effects observed in some haematological malignancies provides ultimate 
evidence for the importance of this pathway in cancer cell survival. 
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Figure 1.4 Timeline of milestones in PI3K research 
 
Abbreviations: PtdIns = phosphatidylinositol, p-Tyr = phosphorylated tyrosines, PI3K=phosphoinositide-3 kinase, SH2=Src homology 2, 
PTEN=phosphatase and tensin homolog, PDK-1=phosphoinositide dependent kinase 1, mTORC=mammalian target of rapamycin complex, 
TSC2=tuberous sclerosis complex2. Pharmacological PI3K inhibitors are highlighted in red. 
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1.2.2 Classification of the PI3K enzymes 
PI3Ks are divided into three classes – I, II and III, on the basis of their structure and lipid substrate 
preferences.92,93 Class I PI3Ks are primarily linked to oncogenesis because of their ability to convert 
PI(4,5)diphosphate to the important second messenger PI(3,4,5)triphosphate, which from here on 
will be referred to as PIP2 and PIP3. PI3K classes II and III convert PI to PI(3) monophosphate, and 
PI(4)monophosphate to PI(3,4)diphosphate but little is known about the role of these 2 classes of 
enzymes in oncogenesis, if any, and hence they will not be discussed further. PTEN (phosphatase 
and tensin homolog) is an antagonist phosphatase that converts PIP3 back to PIP2 (Figure 1.5). Class 
I enzymes have four 110kD catalytic unit isoforms - p110α, p110β, p110δ and p110γ. These isoforms 
show differential tissue expression in that p110δ and p110γ are highly enriched in leukocytes while 
p110α and p110β are expressed in all tissues.90,118 All class I enzymes are obligate heterodimers and 
have a p85 regulatory subunit, apart from p110γ which binds to a p101 or p87 subunit (Figure 1.6). 
On the basis of their regulatory subunits class I enzymes are further divided into class Ia and Ib 
(Figure 1.6) with class Ia PI3Ks signalling downstream of activated receptor tyrosine kinase (RTKs) 
and class Ib downstream of G-protein coupled receptors (GPCRs).93 This functional distinction is now 
becoming less clear with evidence that molecules such as Ras, which can be activated by either RTKs 
or GPCRs, can in turn activate class Ia and class Ib isoforms.119,120 However this classification is still 
useful, as for instance in the context of p85 activating mutations which result in activation of only 
class Ia isoforms.121  
 
Class Ia isoforms form the main focus of this research for three main reasons. Firstly, p110δ is highly 
enriched in leucocytes90,91 and is the primary isoform involved in B-cell receptor (BCR) signalling.122, 
123 Secondly, although p110γ is also enriched in leucocytes, p110γ-deficient mice are found to 
primarily suffer T-cell defects while p110δ-deficient mice primarily suffer B-cell defects.124 Finally, 
activating oncogenic mutations of PI3K have only been described in relation to class Ia 
isoforms.107,121 
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1.2.3 Class Ia PI3K: Role in normal and malignant cells  
PI3Ks were first discovered in the context of oncogenic cellular transformation but we now know 
that class I PI3Ks play an important role in a number of physiological processes such as immunity, 
metabolism, proliferation and survival. Most of these processes are enhanced or altered in 
malignant cells to provide them an advantage over normal cells. PI3K activation in healthy cells is 
mostly agonistic and driven by growth factors, antigenic stimuli (in B and T-lymphocytes) and 
metabolic changes. In malignant cells, in addition to agonistic signalling, a number of mechanisms 
for constitutive PI3K activation have been described and some of these are discussed below in 
relation to the components of the PI3K signalling machinery. 
 
The p85 regulatory subunit: The class Ia regulatory subunit genes reside on the long arm of 
chromosome 5. PIK3R1 encodes the isoforms p85, p55α and p50α through differential promoter 
usage while PIK3R2 and PIK3R3 encode p85β and p55γ respectively. The inter-SH2, p110 binding 
domain links the regulatory subunit to the catalytic subunit and as a result stabilises as well as 
inhibits the kinase activity of the enzyme. On growth factor stimulation, class Ia PI3Ks are recruited 
to the cell membrane and the p85 subunits bind to phosphorylated tyrosine motifs or Ras through 
their respective binding domains. This binding releases the inhibitory effect of P85 on the catalytic 
subunits while also approximating them to their substrate PIP2, thereby triggering the PI3K signalling 
cascade.  
 
It is not known whether each of the p85 isoforms have distinct roles but there is evidence for 
differential binding to receptors. It has also been demonstrated that p85 regulatory subunits can 
bind any of the class Ia p110 isoforms and there is no evidence for preferential binding.90 It is 
therefore likely that this pairing depends, at least to some extent, on the relative abundance of the 
p110 isoforms.  
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Figure 1.5 Conversion of PIP2 to PIP3 by class I PI3K and antagonism by the phosphatase PTEN 
 
 
Figure 1.6 Classification of class I PI3K isoforms 
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Somatic mutations in PIK3R1, the gene encoding p85, p55α and p50α, were first described in 
association with ovarian and colorectal carcinomas125. These mutations were found to be 
predominantly localised to the inter SH2, p110 binding domain and were shown to constitutively 
activate PI3K, thereby establishing their oncogenic potential. This was confirmed more recently 
when frequent somatic mutations in the inter-SH2 regions of PIK3R1 were described in colon cancer 
(9/108) and were shown to promote cell survival in a p110-dependent manner121. Moreover, it was 
recognised that these mutations may provide a mechanism for global class Ia activation.  
 
The class Ia p110 catalytic subunits: The genes encoding p110α (PIK3CA), p110β (PIK3CB) and p110δ 
(PIK3CD) reside on chromosome 3. As mentioned previously, p110α and β are widely expressed in 
mammalian tissue. Genetic lack of p110α or p110β in mice is associated with embryonic 
lethality.110,126 However, selective conditional knock out/ knock-in models and pharmacological 
inhibitors of p110α have demonstrated an important role for this isoform in proliferation, growth 
factor and insulin signalling.112,127,128 This isoform has also been reported to play an important role in 
angiogenesis.129 Studies of the PIK3CA promoter have observed that expression of this isoform can 
be regulated positively by FOXO3a130 and NF-κB131 and negatively by p53.132  Conditional p110β 
knockout mice demonstrate similar defects in insulin signalling, cell trafficking and proliferation.133 In 
addition p110β plays an important role in PI3K activation in platelets and thrombus formation.117,134 
Little is known about the factors controlling the expression of PIK3CB.   
 
In contrast to p110α and p110β isoforms, p110δ knockout mice are viable but show an immune 
defect. The details of the immune defects observed in p110δ knockout mice compared to the class 
IB p110γ knockout genotype are detailed in table 1.5. The reason for the enrichment of p110δ in 
leucocytes is not entirely clear but is likely to be a combination of lineage specific hypomethylation 
of specific promoter regions in the PIK3CD gene together with leukocyte specific trans-acting 
factors.135,136 
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Table 1.5 Characteristics of p110δ and p110γ knockout mice 
 
Vanhaesebroeck et al. 2005124 
  Studies have demonstrated that the PI3K pathway is a critical survival pathway downstream of the 
BCR137 and p110δ has an essential role in B-cell development and B-cell receptor (BCR) 
signalling.138,139 The BCR in mammalian cells consists of a ligand binding moiety linked to a 
heterodimeric (Ig-α, Ig-β) signal transduction moiety that has a cytoplasmic immunoreceptor 
tyrosine-based activation motif (ITAM). Antigen recognition and binding by the BCR, leads to ITAM 
induced phosphorylation of SYK and LYN which in turn activate a number of downstream pathways 
that mediate B-cell growth, anti-apoptotic effects, proliferation, and increased cell metabolism. 
Phosphorylated SYK and LYN in turn phosphorylate the cytoplasmic YXXM motifs (where X is any 
amino acid) of CD19 and B-cell adaptor for PI3K (BCAP). As mentioned previously, these 
phopshorylated tyrosine motifs are recognised by the p85 regulatory subunit of PI3K resulting in 
35 
 
recruitment of the PI3K heterodimer to the cell membrane thereby leading to conversion of PIP2 to 
PIP3. PIP3 recruits proteins that have a pleckstrin homology domain, such as AKT, PDK1 and BTK to 
the cell membrane. This leads to phosphorylation of AKT by PDK1 at threonine 308 (thr308). Full 
activation of AKT is achieved by phosphorylation at serine 473 (ser473) by mTOR complex 2 (Figure 
1.7). AKT and its downstream targets such as mTOR are key effectors in the PI3K pathway and are 
discussed further in the next section. In addition to BCR signalling, an important role for p110δ has 
also been described in IL4 receptor signalling in B cells,140 regulation of allergic responses141 and in 
regulatory T-cell function.142 In summary, at least in healthy cells, there appears to be a degree of 
non-redundancy in the functions of the individual PI3K isoforms.  
 
Figure 1.7 Activation of the PI3K signalling cascade downstream of the B-cell receptor 
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The role of PI3K in cancer has been studied best in relation to the class Ia isoforms. PIK3CA is the 
only isoform that has cancer-associated somatic mutations.107 These gain of function mutations were 
initially described in solid tumours and are associated with increased lipid kinase activity, 
constitutive pathway activation and the ability to transform normal cells in vitro and in vivo.143 80% 
of these mutations arise from three hotspots (in exons 9 and 20), two located in the helical domain 
and one in the kinase domain of p110α. Evidence thus far suggests that PIK3CA mutations are rare or 
absent in haematological malignancies. Increased copy number of PIK3CA has been described in a 
number of solid tumours such as breast, thyroid and squamous cell carcinoma and is associated with 
a worse outcome. As discussed later, PIK3CA gene amplification has also been described in mantle 
cell lymphoma and is thought to contribute to pathogenesis.144 The role of PIK3CB in oncogenesis 
has mainly been described in the context of loss of PTEN expression where this isoform appears to 
gain an important role.145 Once again this has only been studied in solid tumours. As previously 
mentioned, similar to PIK3CB, no cancer associated mutations are found with PIK3CD. However, 
both PIK3CB and PIK3CD have been observed to induce oncogenic transformation when over-
expressed in avian cells in culture.146  
 
Signalling outputs: PIP3 is the key product generated by lipid kinase activity of PI3K. An increase in 
PIP3 production, as a result of growth factor or antigenic stimulation, leads to an increase in 
recruitment of proteins that have a PH domain to the cell membrane. These include serine-
threonine kinases such as AKT, PDK1 and tyrosine kinases such as BTK. AKT is the best studied 
downstream target of PI3K and phosphorylation of AKT at thr308 and ser473 is commonly used as a 
marker of PI3K activation. Upon activation, AKT phosphorylates a number of downstream targets 
leading to a net positive effect on cell metabolism, growth, survival and proliferation. Several 
downstream targets of AKT have been described but some of the well described ones are TSC 
(tuberous sclerosis complex), GSK-3β (Glycogen synthase kinase), FOXO1 (forkhead box O 
transcription factor), BAD and MDM2, all of which are inactivated by AKT mediated phosphorylation. 
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Inactivation of TSC leads to mTORC1 mediated phosphorylation of S6K and 4EBP-1 leading to 
increased protein translation. Akt can also activate mTORC1 through inactivation of PRAS40 which 
otherwise inhibits mTORC1 activity. GSK-3β regulates the potentially oncogenic transcription factors 
JUN and MYC and also phosphorylates and mediates nuclear export of cyclin D1, while FOXO1 has a 
positive effect on the growth attenuating factor p27 and pro-apoptotic BIM. Akt inactivates the pro-
apoptotic BCL2 family member BAD and also phosphorylates MDM2 allowing its translocation to the 
nucleus to inhibit p53.147  
 
Figure 1.8 Important downstream targets of the serine-threonine kinase Akt 
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1.3 MANTLE CELL LYMPHOMA AND THE PI3K PATHWAY 
 
1.3.1 Pre-clinical studies 
Initial evidence for the importance of PI3K signalling in MCL was found in a study comparing gene 
expression profiles in purified MCL cells to their normal counterparts.21 Following this, a study by 
Rudelius et al in 2006 observed that constitutive activation of AKT and its downstream targets was 
commonly found in MCL particularly with the blastoid variant. They found loss of PTEN expression in 
6/31 primary samples but did not detect any mutations in exons 9 and 20 of PIK3CA. They also 
demonstrated that LY294002, wortmannin and an AKT inhibitor were able to block phosphorylation 
of downstream targets and induce growth arrest as well as apoptosis in 2 MCL cell lines Granta 519 
and Z138C.22 A further study by Dal Col et al suggested that a phosphorylated inactive form of PTEN 
correlated with constitutive activation of Akt in MCL. Using LY294002 and the mTORC1 inhibitor 
Rapamycin, they demonstrated that while both inhibitors were able to antagonise IL4 and CD40L 
induced proliferation of MCL, PI3K inhibition was also able to induce apoptosis in primary samples.23 
Both studies described reduction in cyclin D1 levels in response to these inhibitors as a result of 
reduction in mTOR induced protein translation of cyclin D1 but also enhanced GSK-3β mediated 
nuclear export of cyclin D1. In addition it has been suggested that Akt can stabilise cyclin D1 mRNA 
by inactivating proteins that bind to mRNA ARE (AU rich elements) to mediate decay.148  
 
Subsequently, while studying the role of PIK3CA in MCL, Psyrri et al found gene amplification of 
PIK3CA in 15/22 primary MCL (68%) and 2 cell lines (Granta519 and REC-1) related to a gain of 
PIK3CA copy number (>3). Once again, no PIK3CA mutations were detected but loss of PTEN 
expression was found using IHC in 5/33 MCL. Only one of the five samples with loss of PTEN 
expression also had PIK3CA gene amplification. Constitutive AKT phosphorylation was found in 7 out 
of 12 cases with PIK3CA gene amplification. This study was limited by the fact that other class Ia 
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isoforms were not studied, the role of isoform selective inhibition was not evaluated and findings 
were not correlated with clinical status of the patient. 
 
Although there is no direct evidence for the oncogenic role of p110δ, its key role in B-cell survival 
and high expression in leucocytes make it an attractive target in lymphoid malignancy. The first 
highly selective p110δ inhibitor CAL-101 or GS-1101, now known as Idelalisib, was shown to 
significantly inhibit constitutive Akt phosphorylation (p-AKT) to a similar extent in primary MCL and 
CLL cells in vitro.149 It was also shown to attenuate increases in p-AKT induced by BCR and soluble 
CD40 ligand stimulation. In addition GS-1101 was shown to counteract chemotactic signals and 
overcome the protective effect of nurse-like cells in CLL co-culture models.150,151  
 
There is therefore good pre-clinical evidence for PI3K signalling in the pathogenesis and survival of 
MCL. PIK3CA amplification appears to be an important aberration but the reasons for and 
implications of this aberration have not been studied. Loss of PTEN expression appears to be a 
relatively common mechanism for constitutive activation of this pathway and is thought to occur in 
15-20% of cases. More recently, 13q31-q32 amplification, one of the common secondary genetic 
alterations in MCL, has been shown to lead to PTEN inactivation via microRNAs miR 17~92 providing 
another mechanism for PI3K activation.152 However, these studies do not address the relative role of 
the class Ia isoforms in MCL or biomarkers that may predict sensitivity to isoform-selective or pan-
PI3K inhibition. The pre-clinical data discussed above is summarised in Table 1.6. 
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Table 1.6 Pre-clinical evidence for the role of PI3K signalling in MCL survival and pathogenesis 
 
 
 
 
 
 
 
 
 
41 
 
1.3.2 Clinical activity of GS-1101 in MCL  
Results from phase I trials of the first PI3K p110δ selective inhibitor GS-1101 were reported at the 
annual meeting of the American Society of Hematology in 2010.153 The study included patients with 
relapsed/ refractory indolent and aggressive NHL (Table 1.6). A dose escalation starting at 50mg BID 
and going up to 350mg BID was undertaken. Plasma Cmax and AUC did not increase significantly 
beyond a dose of 150mg BID and MTD was not reached. An interesting redistribution of lymphocytes 
resulting in lymph node shrinkage and transient peripheral blood lymphocytosis was observed and is 
thought, at least in CLL, to be due to abrogation of chemokine mediated migration and homing of 
tumour cells.151 This phenomenon was also observed subsequently in early phase studies with the 
BTK inhibitor Ibrutinib, another key ‘second messenger’ in BCR signalling. Apart from a reversible 
transaminitis seen in some patients, GS-1101 was well tolerated in the majority of patients. 
 
Table 1.7 Clinical characteristics of patients enrolled in the phase I study of CAL-101/GS-1101 
Characteristics MCL (N=21) iNHL (N=30) CLL (N=54) 
Age, median 
[range], years 
71 
 [52-82] 
61.5 
[32-85] 
62.5 
 [37-82] 
Bulky disease, % 57 50  81 
Adverse genetics (del 17p), % -- --  36 
Prior therapies, median  
[range] 
5 
 [1-12] 
4 
[1-10] 
5 
[2-15] 
Prior therapy type, %    
Rituximab 100 100   98 
Alkylating agent 100   87   87 
Anthracycline   95   50   -- 
Purine analog --   30 100 
Bortezomib (MCL)/Alemtuzumab (CLL) 76 -- 31 
Kahl et al ASH annual meeting 2010 
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In relation to MCL, responses with GS-1101 were reported for 21 patients with relapsed/refractory 
disease. The median number of prior therapies in patients with MCL included in this study was 5 
(range 1-12). The best on-treatment change in tumour size in MCL compared to CLL and indolent 
NHL (follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma and 
lymphoplasmacytic lymphoma) along with the median duration of response in these groups of 
patients is depicted in the waterfall plot in figure 1.9A. While the response rates in MCL (best on-
treatment response) with single agent GS-1101 in this heavily pre-treated cohort is still impressive, a 
markedly greater proportion of patients with CLL and indolent NHL achieved a greater than 50% 
reduction in tumour size with fewer progressions while on treatment (Hallek criteria 2008). In 
addition, the duration of response was markedly shorter in MCL patients compared to both CLL and 
indolent NHL (Figure 1.9B). 
 
Figure 1.9 Best on-treatment response (A) and duration of response (B) with CAL-101/ GS-1101 in 
MCL, CLL and indolent NHL (iNHL) 
Kahl et al. ASH Annual meeting 2010 
A. 
B. 
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1.3.3 Summary and rationale for studies presented 
While pre-clinical studies provide good evidence for a role for the PI3K pathway in the pathogenesis 
of MCL, the relative role of the class Ia isoforms, which are the best studied isoforms in PI3K 
mediated oncogenesis, is not clear in this disease. B-cell receptor signalling is important for healthy 
B-cell survival but also appears to play a role in malignant B-cell survival as shown not only by 
evidence of bias in the IGHV repertoire and constitutive activation of BCR activation related 
pathways, but also from the clinical activity of highly selective small molecule inhibitors of the BCR 
signalling cascade.   Some of these inhibitors have been evaluated in MCL and are depicted in figure 
1.10.  
 
Figure 1.10 The BCR signalling cascade and targets under evaluation in MCL 
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The p110δ isoform is a key component of BCR signalling and is enriched in leucocytes making it an 
attractive target. However, phase I studies with the highly selective p110δ inhibitor CAL-101/GS-
1101 have demonstrated relatively inferior activity in MCL compared to CLL and indolent NHL. With 
evidence that loss of PTEN expression and gene amplification of PIK3CA are relatively common in 
MCL, it is important to investigate the relative role of the class Ia isoforms in this disease.  
 
Targeting more isoforms is likely to be associated with greater toxicity but although genetic deletion 
of p110α and p110β knock out in mice is associated with embryonic lethality, pharmacological 
inhibition with PI3K inhibitors that target multiple isoforms appear to be well tolerated in patients. 
This may be the result of a more selective effect on the ‘PI3K’ addicted tumour cells. One such 
example is GDC-0941, an orally bioavailable PI3K inhibitor that was designed for use in solid tumours 
on the basis that PIK3CA mutations occur at a high frequency of in this group of patients. GDC-0941 
has activity against both wild-type and mutated PIK3CA but is equally selective for PIK3CD/p110δ. In 
early phase trials, GDC-0941 has been reasonably well tolerated with grade 1-2 gastro-intestinal 
symptoms, fatigue and in some cases hyperglycaemia as the main side-effects.154 We therefore 
elected to evaluate this inhibitor in our studies. 
 
While in vitro studies of these drugs are valuable, there is also a need for a pre-clinical in vivo model 
to study drug delivery and activity of these PI3K inhibitors. An in vivo model of MCL would be 
particularly valuable for evaluation of rational drug combinations and biomarkers that emerge from 
in vitro studies. The currently available murine models of human MCL are xenografts (subcutaneous 
and disseminated) of MCL cell lines in severe combined immunodeficient (SCID) mice. 155,156 The only 
primary human MCL mouse model described in the literature was established by injection of CD19 
selected primary MCL cells into human embryonic bone grafts that were implanted subcutaneously 
in SCID mice (SCID-Hu).157  SCID mice without the bone grafts did not show engraftment. This is not 
easily reproducible because of the difficulty and cost involved in obtaining human embryonic bone 
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grafts. Another factor that may have limited the development of a mouse model of human MCL 
could be the availability of adequate tumour cells for injection into mice. The unique position of 
being in a centre with access to a large tissue bank of MCL patient samples and access to NSG mice 
(non-obese diabetic/severe combined immunodeficient/interleukin-2 receptor γ chain–null) through 
collaboration with Dominique Bonnet’s group led us to evaluate this model as a host for primary 
MCL in our studies. NSG mice lack NK cells in addition to mature T or B cells and have been shown to 
permit engraftment of a wider range of primary human cells compared to earlier strains.158 The 
following section details the hypothesis and aims of this research based on the issues highlighted 
above. 
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HYPOTHESES AND AIMS 
 
Hypothesis 1: The relative expression of class Ia PI3K isoforms and mechanism of PI3K activation can 
inform the use of isoform-selective inhibitors in mantle cell lymphoma. 
Aims 
1. Evaluate expression of the class Ia isoforms in MCL by immunohistochemistry and real-time 
PCR. 
2. Evaluate mechanisms of constitutive activation – PIK3CA mutations, PIK3R1 mutations and loss 
of PTEN expression. 
3. Using isoform-selective inhibitors, examine the relative contribution of the class Ia isoforms in 
BCR signalling and constitutive PI3K activation. 
4. Evaluate the cytotoxicity of isoform-selective inhibitors in MCL cell lines and primary samples in 
relation to isoform expression and mechanisms of constitutive activation. 
 
Hypothesis 2: A disseminated xenograft model of human primary mantle cell lymphoma can be 
established in NSG mice. 
Aims 
1. Study the kinetics and distribution of luciferase transduced MCL cell lines injected into pre-
irradiated NSG mice using bioluminescent imaging. 
2. Study the fate of T-cell depleted primary MCL samples injected into irradiated mice. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 TISSUE CULTURE 
 
2.1.1 Cell lines  
All cell lines were grown in sterile flasks under normoxic conditions (21% O2) with 5% CO2 at 37°C. 
Cells were passaged two or three times a week, depending on doubling time, to maintain optimal 
cell concentration.  Aliquots of cell lines were frozen down and thawed at regular intervals of 3-4 
months and mycoplasma testing was carried out every 8 weeks. Cells were harvested in their 
logarithmic growth phase for experiments. The cell lines listed in Table 2.1 were used in construction 
of a cell-block microarray as discussed later.  
 
The MCL cell lines, Jeko-1 and Granta519, were obtained from Dr. Rebecca Auer and their identity 
was confirmed with short tandem repeat (STR) profiling (LGC standards, Teddington, UK). The 
lymphoblastoid cell line NcNc was purchased from ATCC (LGC standards). These three cell lines were 
used in further experiments as detailed later. All culture media and fetal calf serum (FCS) was 
purchased from Sigma-Aldrich (St Louis, MO, USA) while Gentamicin was purchased from GIBCO (Life 
technologies, Paisley, UK). 
 
2.1.2 Primary samples 
In accordance with the updated Declaration of Helsinki, all samples were obtained under current 
regulatory approval from the local research ethics committee (East London and the City), and after 
informed consent, from patients treated at St Bartholomew’s Hospital. Patient information was 
treated with strict confidentiality and was stored electronically in password protected spreadsheets.   
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Table 2.1 Details of cell lines used for cell-block micro-array construction 
 
 
Mantle cell lymphoma: Solid tissue used in tissue microarray (TMA) construction was fixed in 
formalin and embedded in paraffin (FFPE). Snap-frozen tissue used in experiments was evaluated for 
tumour content using CD20 immunohistochemistry (IHC) and then homogenised using the Qiagen 
TissueLyserII (Qiagen, Hilden, Germany) for DNA, RNA and protein extraction. Mononuclear cell 
suspensions were prepared from peripheral blood (PBMCs) and bone marrow (BM) using Ficoll-
Paque (Miltenyi biotech, Cologne, Germany) density gradient centrifugation. Splenic tissue was 
Cell line Origin Growth medium 
CTS Acute Myeloid Leukaemia RPMI + 10% FCS + 1% Gentamicin 
Fuji Acute Myeloid Leukaemia RPMI + 10% FCS + 1% Gentamicin 
THP1 Acute Myeloid Leukaemia RPMI + 10% FCS + 1% Gentamicin 
MEC-1 High grade transformation of CLL IMDM + 10% FCS + 1% Gentamicin 
Jeko-1 Mantle Cell Lymphoma t(11;14) RPMI + 10% FCS + 1% Gentamicin 
GRANTA519 Mantle Cell Lymphoma t(11;14) DMEM + 10% FCS + 1% Gentamicin 
U266 Multiple Myeloma RPMI + 10% FCS + 1% Gentamicin 
RPMI Multiple Myeloma RPMI + 10% FCS + 1% Gentamicin 
OPM2 Multiple Myeloma RPMI + 10% FCS + 1% Gentamicin 
DoHH2 Diffuse Large B Cell Lymphoma t(14;18) RPMI + 10% FCS + 1% Gentamicin 
SUDHL-6 Diffuse Large B Cell Lymphoma t(14;18) RPMI + 10% FCS + 1% Gentamicin 
SUDHL-8 Diffuse Large B Cell Lymphoma t(8;14) RPMI + 20% FCS + 1% Gentamicin 
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dissected on a pre-cooled thermal tray at 4°C (Biocision, Larkspur, CA) and homogenised by mashing 
over 70μm filters (BD biosciences, Franklin Lakes, NJ, USA). Cells were then washed with phosphate 
buffered saline (PBS) prior to density gradient centrifugation to isolate mononuclear cells.  
 
Samples for density gradient centrifugation were diluted 1:1 in sterile PBS. 35mls of this solution was 
carefully layered over 15 ml of Ficoll-Paque in a 50ml conical tube. Tubes were centrifuged at 400xg 
for 25 minutes after which the upper layer of fluid was carefully aspirated out and the mononuclear 
layer carefully transferred to another 50ml conical tube using a pipette. After performing cell counts, 
cells were cryopreserved in 90% FCS and 10% Di-Methyl Sulphoxide (DMSO, Sigma-Aldrich) at -80°C. 
Cryopreserved cells were thawed in a water bath at 37°C, washed immediately and re-suspended at 
a concentration of 106 cells per ml in Iscove’s modified Dulbecco’s medium (IMDM) with 1mM 
pyruvate, insulin-transferrin-selenium (Life technologies, Paisley, UK), 10% human serum (Sigma-
Aldrich) and 1% Gentamicin, for use in experiments. A total of 22 primary MCL cell suspensions 
confirmed to have more than 85% CD20 positive cells by flow cytometry were used in experiments.  
 
Healthy controls: Healthy B-cells were isolated from healthy volunteer PBMCs using negative 
selection with the B-cell isolation kit II (Miltenyi Biotec). Following density gradient centrifugation 
and determination of cell number, 40µl MACS (Magnetic Cell Separation) buffer (Miltenyi Biotec) 
was added for every 107 cells.  10µl of a biotin antibody cocktail (per 107 cells) against non B cells 
(CD2, CD14, CD16, CD36 and glycophorin A) was added and incubated after mixing at 4ᵒC. Following 
addition of a further 30µl of MACS buffer, cells were incubated with anti-biotin beads (20µl per 107 
cells) for a further 15 minutes at 4ᵒC. Cells were then washed and re-suspended in 500µl MACS 
buffer. LS columns (Miltenyi Biotec) were primed with buffer in the magnetic field of a MACS 
separator (Miltenyi Biotec). Cells were applied gently to the top of the column and the effluent 
consisting of negatively selected B-cells was collected in a 15ml conical tube. Cell counts were 
performed after which cells were either re-suspended in culture medium and used immediately for 
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experiments or cryopreserved at -80ᵒC in 90% FCS and 10% DMSO. Snap frozen or FFPE tonsils used 
as healthy controls were obtained from tonsillectomies performed for non-malignant pathology. 
 
2.2 IMMUNOHISTOCHEMISTRY 
 
2.2.1 Cell block preparation 
Antibodies against p110α, p110β, PTEN and Ki67 have previously been validated for IHC on FFPE 
tissue159 but there was no literature describing the use of a p110δ selective antibody for IHC at the 
time of performing these experiments. In order to evaluate a commercially available p110δ antibody 
(Santa Cruz Biotech, Santa Cruz CA) for use in FFPE tissue, cell blocks were prepared from the cell 
lines listed previously and incorporated into a cell block microarray.  
 
We compared two previously described methods for cell block preparation - one using 2% agar and 
the other involving the use of thrombin or fibrin clot as a matrix. The thrombin cell block preparation 
method 160 was relatively quicker and easier. It was also superior in preserving the morphology of 
cells compared to the agar method. Appendix A contains details of the protocols and a comparison 
of the two methods. 1mm cores in duplicate from formalin-fixed, paraffin-embedded thrombin cell 
blocks were incorporated into a cell block microarray which was then used to validate and optimize 
the p110δ antibody by comparing expression by IHC to that seen by western blotting in the same cell 
lines (Figure 2.1).  
 
Three dilutions, 1:100, 1:250 and 1:500, of the p110δ antibody were evaluated (manufacturer’s 
recommendation 1:50-1:500). A dilution of 1:250 was found to provide optimal staining and was 
able to differentiate high p110δ expressing cell lines from low expressing ones (Figure 2.2). 
 
51 
 
Figure 2.1 Optimisation and validation of an antibody against p110δ: A panel of cell lines (A) were used to prepare a thrombin cell block FFPE microarray 
(B). Simultaneous western blotting was performed on the lymphoma and myeloma cell lines included in this panel (C). 
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Figure 2.2 Optimisation and validation of an antibody against p110δ: A) Bar graph of IHC scores obtained from staining of the cell block microarray with a 
p110δ antibody concentration of 1:250. B) Western blot (same as in figure 2.1) showing comparable intensities of p110δ in the corresponding cell lines. 
MEC-1 (green arrow) exhibits strong expression while OPM2 has little or no expression of p110δ similar to the IHC results. C) Images of p110δ staining of 
cell blocks (original magnification x400) in 3 cell lines MEC-1, THP-1 and OPM2 exhibiting different intensities of staining.  
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2.2.2 Tissue microarray (TMA) preparation, staining and scoring 
 1mm cores from 175 FFPE biopsies taken from 121 patients were arrayed in triplicate onto 6 slides 
(TMA 03A-F). In addition to tumour samples, 3 tonsil controls (TON) and 3 orientation cores (ORI - 
cardiac muscle) were incorporated into each tissue micro-array slide (Figure 2.3A).  
 
TMA slides were heated overnight in an oven at 60°C. Slides were de-waxed with xylene prior to 
antigen retrieval by pressure cooking in a citrate buffer at pH 6. A hydrophobic pen was used to 
mark around the arrays after which slides were loaded onto the Dako Autostainer Plus machine 
(Dako, Glostrup, Denmark).  The appropriate volumes of antibodies and reagents were placed in the 
machine which was then programmed to sequentially incubate slides with primary antibody, super 
enhancer reagent, super sensitive horse radish peroxidise (HRP) labelled polymer and finally a 
diamino benzidine (DAB) substrate (Biogenex, Fremont, CA, USA) at room temperature. Details of 
primary antibodies used are listed in table 2.2. Incubation times for the other reagents are listed in 
table 2.3. Slides were then counterstained with haematoxylin and cover slips were mounted using 
DPX (Di-N-Butyl Phthalate in Xylene). 
 
Table 2.2 Details of primary antibodies and conditions used for immunohistochemistry on MCL TMA 
Primary 
antibody  
Supplier/ code  Species  
(clone)  
Antigen  
retrieval  
Concentration  Incubation  
P110α  Cell Signaling  
#4249  
Rabbit polyclonal  
(C73F8)  
Citrate pH6  1:250  40”  
P110β  Abcam  
ab55593  
Mouse monoclonal  Citrate pH6  1:250  40”  
P110δ  Santa Cruz  
sc-55589  
Mouse monoclonal  
(A-8)  
Citrate pH6  1:500  40”  
PTEN  Cascade  
ABM-2052  
Mouse monoclonal 
(6H2.1)  
Citrate pH6  1:25  60”  
Ki-67 Dako 
M7240 
Mouse monoclonal 
(MIB1) 
Citrate pH6 1:1000 40” 
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Table 2.3 Incubation times for IHC reagents 
IHC Reagent Incubation time 
Super enhancer 20” 
SS HRP labelled polymer 30” 
DAB 10” 
 
 
Phosphoprotein markers of PI3K pathway activation such as phospho-Akt were deliberately excluded 
from IHC analysis as the stability of phosphoproteins has been shown to be highly reliant on the 
interval between removal from the body and fixation. Rapid de-phosphorylation has been observed 
within minutes in the absence of prompt fixation making IHC analysis of phosphoprotein expression 
in FFPE tissue unreliable.161,162 
 
All TMA slides were scanned using an Olympus scanning microscope to obtain high-resolution 
images which were then analyzed using the Ariol SL-50 visual analysis software version 3.2 (Genetix, 
San Jose, CA, USA). Images of cores were screened individually to exclude non-tumor tissue and 
tonsillar germinal centers were selected as controls. The software was trained to calculate the 
percentage of positive cells and mean staining intensity of cores. The immunohistochemistry (IHC) 
score was calculated as the product of percentage positive cells and mean intensity. Maps of tissue 
microarrays were created in order to match tissue cores to the corresponding patient biopsy (Figure 
2.3B). The Ariol visual analysis software assigns an X-Y co-ordinate to each core and the final analysis 
parameters are displayed against the respective X-Y co-ordinate. The parameters were matched to 
the corresponding patient biopsy using the TMA slide map and the X-Y co-ordinate (Figure 2.3C). 
Biopsies with only one evaluable core on the TMA were excluded and IHC scores for duplicates and 
triplicates were averaged for final analysis.  
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Figure 2.3 Example of a MCL TMA slide with the corresponding map designed to match cores on the 
TMA to patient biopsies and clinical information 
 
 The IHC score was validated by arranging images from randomly selected TMA cores in the order of 
increasing IHC scores. Cores from TMA slides stained with p110α were used for validation as they 
showed the widest variation (Figure 2.4). PTEN expression was scored independently by Dr. Abigail 
Lee and myself as 0 (no expression), 1+ (weaker than adjacent normal tissue) or 2+ (same as or 
stronger than normal tissue). Ki-67 was also scored by Dr Abigail Lee and myself, in line with the 
guidance published by the European MCL network.50 Blastoid morphology of MCL biopsies was 
verified by Dr Maria Calaminici. 
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Figure 2.4 Validation of the IHC score (percentage positive x mean intensity) in 16 random TMA cores stained with p110α 
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2.3 WESTERN BLOTTING 
 
2.3.1 Protocol 
Cell lysis buffer was prepared by addition of phosphatase and protease inhibitors (Roche, Basel, 
Switzerland) to cell lysis reagent (CelLyticM, Sigma-Aldrich). Lystaes were prepared by washing cells 
once with ice cold sterile Hank’s solution (Sigma-Aldrich) and centrifuging at 400xg for 5 minutes at 
4°C in pre-cooled Eppendorf vials. Supernatant was aspirated and pellets were dissolved in cell lysis 
buffer (100μl for 5x106) followed by incubation for 20 minutes on ice. Samples were vortexed and 
centrifuged at 20000xg in a pre-cooled centrifuge for 10 minutes at 4°C. Supernatant was carefully 
aspirated and either used immediately for total protein estimation and western blotting, or stored at 
-80°C. For frozen tissue, a scalpel was used to take shavings from the tissue on a thermal tray 
(Biocision) placed over dry ice. These were added to 200µl cell lysis buffer in 2ml Eppendorf vials 
along with a stainless steel bead and homogenised using the Qiagen TissueLyserII (Qiagen). This 
machine uses two oscillating arms, each capable of holding up to 30 Eppendorf vials. The vials were 
placed in pre-cooled vial holders (4ᵒC) and the machine was programmed to oscillate at 20-30 Hz for 
2 minutes or until the tissue was homogenised. 
 
Total protein was estimated using the Pierce BCA protein assay kit (Thermo Scientific, Waltham, MA, 
USA). This assay employs the colorimetric detection of cuprous ions that are formed by reduction of 
the cupric ion in an alkaline medium in the presence of protein. Samples were transferred to a 96 
well plate along with increasing concentrations of bovine serum albumin (BSA) standard. A reagent 
containing bicinchonic acid supplied with the kit was added to the wells following which plates were 
incubated for 20 minutes at 37°C. Absorbance of samples was measured at 562nm on a plate reader 
and total protein was estimated by the software in relation to the BSA standard curve. Volumes of 
samples for equal protein loading were calculated and mixed with NuPage LDS sample buffer (4X) 
(Invitrogen, Life technologies, Paisley, UK) in a ratio of 3:1. Samples were then heated at 95°C for 5 
58 
 
minutes and loaded, along with a protein ladder (Magic Mark XP, Invitrogen), into wells of a NuPage 
4-12% Bis-Tris polyacrylamide pre-cast gel (Invitrogen) for electrophoresis. Gels were placed in 
MOPS running buffer (Invitrogen), resolved at 200 volts and then transferred onto a PVDF 
membrane using the iBlot dry transfer device and transfer stacks (Invitrogen). Following a blocking 
step with 5% BSA, membranes were incubated with primary antibody either overnight at 4°C or at 
room temperature for 2 hours at the recommended dilutions. Membranes were then washed with 
TBS-T (Tris-buffered saline with tween) and incubated with horse radish peroxidase (HRP) labelled 
secondary antibody (Dako) for an hour at room temperature. ECL chemiluminescent reagent (GE 
healthcare, Uppsala, Sweden) was applied to visualize the blots using the Fuji LAS 2000 digital 
imager (Fujifilm, Japan). Membranes were stripped using Restore Plus stripping buffer (Thermo 
Scientific), blocked in 5% BSA and washed prior to further probing. Membranes were stored at -20°C 
by drying between 2 sheets of Whatman paper and were reactivated with methanol when required. 
 
2.3.2 Antibodies and reagents  
Primary antibodies for western blotting against p110α (#4249), GAPDH (#2118), total Syk (#2712), 
phospho-Syk thr525/526 (#2710), total Akt (#9272), phospho-Akt ser473 and thr308 (#9271, #2965), 
phospho-GSK3b ser9 (#9323), total ribosomal S6 (#2217) and phospho-S6 ser235/ser236 (#2211) 
were purchased from Cell Signaling technologies (Danvers, MA, USA). Antibodies against p110β (sc-
602) and p110δ (sc-55589) were purchased from Santa Cruz biotechnology (Santa Cruz) and anti-
human PTEN (ABM-2052) from Cascade bioscience (Winchester, MA, USA). 10 X Tris buffered saline 
with 1% Tween 20 (TBS-T) was prepared by adding 24.1g tris HCl and 80g NaCl to 950mls of distilled 
water. Hydrochloric acid or sodium hydroxide was added to adjust the pH to 7.6. 5% BSA (Sigma-
Aldrich) or 5% milk (Marvel, UK) in 1x TBS-T wash buffer was used to prepare antibody dilutions. 
 
2.3.3 Densitometry 
Densitometry was performed on GelScan Standard software v5.1 (BioSciTec, Frankfurt, Germany). 
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2.4 PI3K INHIBITORS AND CELL STIMULATION  
 
GDC-0941 was purchased from Selleck Chem (Houston, TX, USA) while CAL-101/GS-1101 was 
purchased from Active Biochem (Maplewood, NJ, USA). Figure 2.5 shows the chemical structure and 
IC50 (half maximal inhibitory concentration against recombinant enzyme) values for GS-1101
149 and 
GDC-0941163 against the 4 class I PI3K isoforms. In addition, a selective p110α inhibitor A66164 and a 
selective p110β inhibitor TGX-221117 were purchased from Selleck Chem. 10mM stock solutions were 
prepared in DMSO and stored at -20°C. Serial dilutions for drug treatment were prepared in cell 
growth medium and cells were treated in their logarithmic growth phase. 
 
Figure 2.5 CAL-101/GS-1101 and GDC-0941: Chemical structures and IC50values for class I PI3K  
 
 
Goat anti-human IgM F(a’b)2 fragments (Southern Biotech, Cambridge, UK) were used to activate the 
BCR signalling cascade and study the effect of isoform-selective PI3K inhibition on downstream 
targets in this setting. Cells were treated with pharmacological inhibitors or vehicle for an hour prior 
to incubation with 10µg/ml IgM F(a’b)2 for 10 minutes. Protein was extracted from cells at this point 
for western blotting. Recombinant interleukin 4 (IL4) (Sigma-Aldrich) was used to induce 
proliferation of primary MCL cells. Cells were incubated with 20ng/ml IL4 prior to treatment with 
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either vehicle or increasing concentrations of PI3K inhibitors in a 96-well plate. An ATP cytotoxicity 
assay was used at 72 hours to assess the effect of PI3K inhibition on IL4-stimulated cells. 
 
2.5 REAL TIME QUANTITATIVE PCR MEASUREMENT OF GENE EXPRESSION 
 
2.5.1 RNA extraction 
RNA was extracted from cell lines and primary MCL cell suspensions (5x106) using the RNeasy mini 
kit (Qiagen, Hilden, Germany). Cells were lysed in a denaturing buffer (Buffer RLT) containing 
guanidine-thiocyanate to inactivate RNAses. Lysates were homogenised using QIAshredder spin 
columns (Qiagen) by loading up to 700µl of lysate into a column placed in a 2ml collection tube and 
centrifuging at full speed for 2 minutes. Ethanol was added to the homogenised lysate to facilitate 
binding of RNA to the silica membrane in the RNeasy spin columns. Lysates were loaded onto the 
spin columns and contaminants were washed off the silica membranes by centrifuging columns with 
the buffers provided (Buffer RW1 and Buffer RPE). Finally, total RNA was eluted from the silica 
membrane using RNase free water.   
 
RNA was extracted from frozen tissue (tonsil and MCL lymph nodes) using a Trizol based method. 
Shavings of frozen tissue were placed in 2ml Eppendorf vials containing 1ml Trizol (Qiagen) and 
homogenised with the Qiagen TissueLyserII as described for protein extraction.  The homogenate 
was allowed to rest for 5 minutes before addition of 200µl chloroform. After vortexing vigorously, 
the homogenate was centrifuged and the upper aqueous phase containing RNA was isolated. 
Isopropanol was used to precipitate the RNA by centrifugation and the pellet was washed with 1ml 
75% ethanol prior to air drying and dissolution in RNAse free water. RNA quantity and purity were 
measured using a Nanodrop ND-1000 spectrophotometer (Nanodrop technologies, Wilmington, DE, 
USA) and RNA samples were stored at -80°C. 
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2.5.2 cDNA synthesis  
The high capacity reverse transcription kit (Applied Biosystems, Life Technologies, Paisley, UK) was 
used to prepare a 2xRT Master Mix (10µl per reaction) as shown in table 2.4. 2µg RNA in a volume of 
10µl was added to this to make up a reaction volume of 20µl per 0.2ml PCR reaction tube. 
 
Table 2.4 Components of 2x RT Master Mix used for cDNA synthesis 
2xRT master mix 
Volume per reaction (µl) 
10 x RT Buffer 2 
25 x dNTP Mix (100mM) 0.8 
10 x RT Random Primers 2 
Multiscribe Reverse Transcriptase 1 
Nuclease free water 4.2 
 
 
Reverse transcription was carried out in an automated thermal cycler with initial annealing for 
10min at 25°C, followed by extension for 120 min at 37°C, reverse transcriptase inactivation for 5 
min at 85°C and finally cooling to 4°C.  
 
2.5.3 Quantitative real-time PCR  
Quantitative real-time PCR (qRT-PCR) was performed using TaqMan gene expression assays (Applied 
Biosystems) for PIK3CA (Hs00192399_m1), PIK3CB (Hs00927728_m1) and PIK3CD (Hs00180679_m1) 
with GAPDH (Hs99999905_m1) as endogenous control. TaqMan gene expression Master Mix 
(Applied Biosystems) and cDNA were added to TaqMan gene expression assays and a final volume of 
20µl per reaction (Table 2.5) was added to individual wells of a Fast Optical 96 well reaction plate 
(Applied Biosystems).  
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Table 2.5 Components of PCR reaction mix for quantitative real time PCR 
PCR reaction mix components 
Volume per 20µl reaction (µl) 
20 x Taqman gene expression assay 1 
2 x TaqMan gene expression Master Mix 10 
cDNA template 2 
RNase free water 7 
 
 
The plate was sealed with an optical adhesive cover and loaded on the ABI HT-7900 instrument 
(Applied Biosystems).  Quantitative fast real-time PCR was performed with an initial denaturation 
step at 95ᵒC for 10 minutes followed by 40 cycles at 95ᵒC for 1 second and 60ᵒC for 20 seconds. Data 
was analyzed using the SDS2.1 software (Applied Biosystems) and relative expression values were 
calculated using the ΔCt method with GAPDH as endogenous control. All reactions were run in 
triplicate. 
 
2.6 PIK3R1 AND PIK3CA MUTATION ANALYSIS 
 
2.6.1 DNA extraction 
Genomic DNA was extracted from cell lines, primary MCL cell suspensions and homogenised frozen 
sections using the DNeasy mini kit (Qiagen). Briefly, protein digestion was carried out by addition of 
proteinase K and buffer AL followed by incubation of samples at 56°C for 10 minutes. Samples were 
mixed thoroughly with 96-100% ethanol and loaded into the DNeasy spin columns. DNA was isolated 
on the membrane of the column by centrifugation. Contaminants and enzymes were washed off by 
centrifugation of columns in the presence of buffers provided (Buffer AW1 and AW2). DNA was then 
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eluted from the membrane using buffer AE. DNA content and purity were checked using a Nanodrop 
ND-1000 spectrophotometer and samples were stored at 4°C. 
 
2.6.2 PCR, purification and sequencing 
Primers used for PCR amplification of PIK3CA exons 9 and 20 and PIK3R1 exons 9, 10, 11, 13, 15 and 
16 were designed using the Primer3 software165. Primers were purchased from Sigma-Aldrich and 
are listed in table 2.6.  
 
Table 2.6 
Gene 
Exon Forward primer  Reverse primer  
PIK3R1 
9 CTATGTGGGCAGGAGGAATA AACTGAAGGTTAATGGGTCAGA 
10 TGGTACGAGATGCGTCTACT CAAAATAGCTGACATGGAAACATCT 
11 GTTACGATGTTTAGACAAGATCCTT GCTTCAGTTATCACGTGAACTTAAT 
13 AAAATATGTTGAGCCACTCCAAA GTTTTCATTGCCCAACCACT 
15 AAAACTCAGGTCGGGCAGA AGCTGCTTTGGTTTCTCTTCTA 
16 TTACCTACCCAAGGCACTCG GCCTTAGGCTGCATGTCTTC 
PIK3CA 
9 TGGCCAGTACCTCATGGATT TAAAGCCCTAGCTTGCCTTC 
20 TTTTGGGAATTGGAGATCGT GCTGGTTTCAATTCCTGAGC 
 
 
A PCR reaction mix (20μl per reaction) consisting of 1μl of genomic DNA or non-template control, 
0.5μl each of forward and reverse primers and 17μl Reddy mix (Thermo Scientific) was prepared. 
PCR was performed in an automated thermal cycler (MJ research, Waltham, MA USA) with initial 
denaturation at 95°C for 5 minutes followed by 34 cycles of denaturation for 30 seconds, annealing 
at 95°C for 30 seconds and extension for 72°C for 30 seconds followed by a final extension step at 
72°C for 5 minutes. Amplicons were evaluated using agarose gel electrophoresis and visualized by 
trans-illumination under ultraviolet light. Enzymatic purification of products was carried out using 
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ExoSAP solution which was prepared by mixing 1μl Exonuclease1 (Promega, Madison, WI), 20μl 
Shrimp Alkaline Phosphatase (New England biolabs, Ipswich, MA) and 179μl distilled water. 4μl of 
ExoSAP was added to 5μl of PCR products and placed in an automated thermal cycler at 37°C for 30 
minutes and 80°C for 15 minutes prior to storage at 4°C. Bidirectional Sanger sequencing was 
performed on the purified PCR products using the BigDye Terminator v3.1 cycle sequencing kit 
(Applied Biosystems). A 20μl sequencing reaction mix was prepared consisting of 0.5μl Big Dye 
Terminator mix, 3.75μl 5x Buffer and 1μl of sequencing primer added to 2μl of the purified DNA in 
water. This was placed in an automated thermal cycler with initial denaturation for 1 minute at 96°C 
followed by 26 cycles of denaturation at 96°C for 1min, annealing at 50°C for 15 seconds and 
extension at 60°C for 4minutes before storage at 12°C. Samples were then transferred to the CRUK 
sequencing services at Lincoln’s Inn fields.  Sequences were screened for mutations using the 
sequence alignment editor BioEdit version 7.1.9 (Ibis Biosciences, Carlsbad, CA, USA). 
 
2.7 FLOW CYTOMETRY AND CYTOTOXICITY ASSAYS 
 
2.7.1 Cell counts and viability 
All cell counts for setting up experiments were performed on the Vi-Cell XR Cell Viability Analyzer 
(Beckman Coulter, Indianapolis, IN, USA) which is a coulter counter that incorporates automated 
trypan blue nuclear staining of dead cells to determine the viable cell percentage and number. 
 
2.7.2 Immunophenotyping 
Tumour content of MCL cell suspensions was verified using CD20 immunophenotyping by flow 
cytometry. Only samples with greater than 85% CD20 content were used in experiments. For 
xenograft studies, CD5/CD20 dual staining was carried out along with CD3, CD4 and CD8 staining to 
assess T cell content and subsets. The following fluorochrome conjugated antibodies - CD20-FITC, 
CD5-PE, CD3-APC, CD4-FITC and CD8-PE were purchased from Miltenyi Biotec. For flow cytometry 
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analysis, cells were washed with ice cold staining buffer (PBS + 2%FCS + 0.1% azide) and 
approximately 106 cells in 100µl of staining buffer were incubated with the recommended 
concentration of fluorochrome conjugated antibody. After incubation in the dark at 4ᵒC for 30 
minutes, cells were washed twice and re-suspended in 500µl of staining buffer. DAPI (0.5µg/ml) was 
added for live-dead discrimination. Data was acquired on BD LSR-Fortessa (BD biosciences) and 
analysed using FlowJo version 8.8.7 (TreeStar Inc, Ashland, OR, USA). 
 
2.7.3 Annexin V / propidium iodide staining 
The ApoTarget Annexin V-propidium iodide (PI) kit (Invitrogen), was used for detecting apoptosis in 
MCL cell lines following treatment with PI3K inhibitors. Cells were treated in their logarithmic growth 
phase with increasing concentrations (0.1, 1, 5 and 10µM) of PI3K inhibitors or vehicle control. After 
72 hours of incubation in normoxic conditions at 37ᵒC, cells were washed twice with PBS and re-
suspended in the Annexin V binding buffer provided with the kit. Approximately 2x105 cells in 100µl 
of staining buffer were incubated at room temperature with 5µl of FITC labelled Annexin V and 10µl 
propidium iodide, for 15 minutes in the dark. After this, 400µl of staining buffer was added to each 
tube and cells were analysed by flow cytometry. All experiments were done in triplicate. 
 
2.7.4 Guava ViaCount 
The Guava EasyCyte Plus instrument (Millipore, Billerica MA) is a bench top flow cytometer that can 
acquire samples from 96 well plates. The Guava ViaCount assay uses nuclear binding dyes to provide 
total and viable cell counts and was used to assess growth inhibition in cell lines following PI3K 
inhibition. Cells were treated in their logarithmic growth phase with increasing concentrations (0.1, 
1, 5 and 10µM) of PI3K inhibitors or vehicle, in triplicate, in a 96 well plate. Each well was loaded 
with 2x104 cells in a volume of 120µl. After 72 hours of incubation in normoxic conditions at 37ᵒC, 
120µl of the Guava ViaCount reagent (Millipore) was added to each well and mixed by pipetting. The 
96 well plate was loaded into the EasyCyte plus instrument and the software was programmed to 
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acquire 2000 events per well. Acquisition and analysis were performed on the Guava Cytosoft 
software. All experiments were performed in triplicate. 
 
2.7.5 ATP proliferation and cytotoxicity assay 
The ATP vialight plus kit (Lonza, Basel, Switzerland) was used to assess proliferation in MCL primary 
samples in response to IL4 as well as cytotoxicity in response to PI3K inhibition. This luminescence 
assay is based on the principle that luminescence generated by luciferase in the presence of ATP and 
luciferin is proportional to ATP levels in the sample which in turn reflects cell number and viability. 
        Luciferase 
ATP + Luciferin + O2      Oxyluciferin +AMP + CO2 + Light 
Mg++ 
 
Cells were incubated in triplicate in a 96 well plate after treatment with PI3K inhibitors or vehicle 
using the same protocol as for the Guava ViaCount assay. However, for primary cells a concentration 
of 5x104 cells in 100µl of medium per well was used. In order to assess the effect of PI3K inhibition 
on IL4 stimulation, cells were stimulated with IL4 as detailed previously and were subsequently 
treated with vehicle or increasing concentrations of PI3K inhibitors. Proliferation was compared with 
non-stimulated cells. After 72 hours of incubation in normoxic conditions at 37ᵒC, cells were lysed in 
96 well plates for 10 minutes with the lysis buffer provided in the kit and then transferred to an 
opaque 96 well plate. Cells were incubated with the ATP vialight plus reagent for 2 minutes and 
luminescence readings were acquired on a FluoStar Optima plate reader (BMG labtech, Ortenberg, 
Germany).  
 
2.8 XENOGRAFT STUDIES 
 
Xenograft studies in NSG mice were carried out in collaboration with Dominique Bonnet at the 
Haematopoietic stem cell laboratory, Cancer Research UK, Lincoln’s Inn fields.   The Jeko-1 cell line 
67 
 
and primary MCL samples were provided by the Centre for Haemato-Oncology. Luciferase 
transduction of Jeko-1, tail vein injection into NSG mice and bioluminescent imaging was carried out 
at Lincoln’s Inn fields by Linda Ariza McNaughton (L.A.M.). Primary samples were characterised by 
flow cytometry, T-cell depleted and transported to our collaborators for injection into NSG mice by 
myself. Flow cytometry on mouse derived cells was carried out by L.A.M. while harvest of organs 
from NSG mice was carried out at Lincoln’s Inn fields by L.A.M. and myself. Organs were transported 
back to Barts Cancer Institute in neutral buffered formalin for immunohistochemistry or ice cold PBS 
for isolating cells. Immunohistochemistry on mouse derived tissue was performed by me with 
assistance from Andrew Clear. Cells were isolated from spleens of NSG mice by myself and 
transported for IGH: CCND1 fluorescent in situ hybridisation (FISH) to the cytogenetics laboratory at 
the Royal London hospital where FISH was performed by Amy Roe and Debra Lillington. Details of 
these methods are included in Chapter 6, apart from immunophenotyping of primary samples which 
is detailed in the flow cytometry section of this chapter. 
 
2.9 STATISTICAL ANALYSIS 
 
Prism version 5.03 (GraphPad, La Jolla, CA) was used for statistical analysis. Normally distributed 
data sets were tested with paired or unpaired t-tests, as appropriate, while for 3 data sets, one-way 
analysis of variance (ANOVA) followed by a Bonferroni multiple comparison post-hoc analysis was 
used. Data sets that were not normally distributed were analyzed using the Mann-Whitney test for 
unpaired samples or the Wilcoxon matched-pairs signed rank test for paired samples. P-values less 
than 0.05 were considered significant. Any additional statistical methods are mentioned in the 
relevant sections. 
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CHAPTER 3: IMPORTANCE OF CLASS IA PI3K ISOFORMS AND PTEN 
EXPRESSION IN MCL 
 
3.1 INTRODUCTION 
 
The expression of the three class Ia PI3K isoforms has not been evaluated simultaneously in previous 
studies of MCL. The study that initially reported gene amplification of PIK3CA in MCL did not 
evaluate the expression of the other class Ia isoforms and also did not study the effect of isoform 
selective inhibitors in the setting of PIK3CA gene amplification.144 Studies reporting the activity of 
CAL-101/GS-1101 reported high p110δ expression in MCL but did not explore the expression of 
other isoforms.  
 
Loss of expression of the tumour suppressor PTEN has been evaluated in two separate studies of 
MCL and has been found in 15-20% of cases.22,144 Although, phosphorylated PTEN, evaluated by IHC, 
has been reported in one study as a marker of PTEN inactivation,23 the stability of phosphoproteins 
in FFPE tissue is a concern161,162 and we therefore did not evaluate this, or other phosphoproteins 
markers of pathway activation in our studies. 
 
As the first step towards exploring the relative importance of the class Ia PI3k isoforms in MCL, we 
evaluated the protein expression of the three class Ia isoforms and PTEN using 
immunohistochemistry. Clinical associations of loss of PTEN expression, class Ia PI3K isoform 
expression, blastoid morphology and Ki-67 were explored. The effect of isoform selective inhibition 
was studied in relation to PIK3CA gene amplification and agonist-induced BCR signalling in MCL cell 
lines. In view of studies in solid tumours that have demonstrated an important role for p110β in cells 
that lack PTEN expression,145  the value of adding a p110β inhibitor to CAL-101/GS-1101 was studied 
in primary MCL samples exhibiting this phenotype. 
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3.2 MATERIALS AND METHODS 
 
Immunohistochemistry 
As detailed in chapter 2, 175 biopsies from 121 patients were incorporated into the MCL TMA for 
immunohistochemical analysis using antibodies against p110α, p110β, p110δ and PTEN. 
Characteristics of the samples included in the TMA are listed in table 3.1. There was some attrition in 
the number of evaluable samples with serial sectioning of blocks due to poor quality cores, loss of 
cores and exclusion criteria for analysis (only biopsies with at least two evaluable cores were 
included). This explains the discrepancy in the number of samples described in table 3.1 and the 
number finally evaluated in the experiments that follow. The IHC score (product of percentage 
positive and mean intensity) generated with the Ariol visual analysis software was used as a measure 
of protein expression of PI3K isoforms in MCL biopsies and tonsil controls. PTEN and Ki-67 were 
scored manually as described in the previous chapter. IHC scores were matched to patient biopsies 
and clinical information was stored in password protected spreadsheets. Kaplan-Meier survival 
curves were generated using the X-tile software.166 A KI-67 cut-off value of 30% was employed as per 
the recent British Committee for Standards in Haematology (BCSH) recommendations.167 Prism 
version 5.03 (GraphPad, La Jolla, CA) was used for all other statistical analysis. 
 
Quantitative real-time PCR 
The Granta519 MCL cell line was used as it has been shown to exhibit gene amplification of PIK3CA 
associated with increased PIK3CA copy number.144 RNA was extracted from Granta519 and the 
lymphoblastoid cell line NcNc using the Qiagen RNeasy mini kit (Qiagen). Gene expression of PIK3CA 
was evaluated by qRT-PCR using TaqMan gene expression assay Hs00192399_m1 (Aplied 
Biosystems). Data was analyzed using the SDS2.1 software (Applied Biosystems).  
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Table 3.1 Characteristic of MCL biopsies included in TMAs for IHC analysis 
 
 
 
 
 
 
Period over which biopsies taken 1972-2008 
Total biopsies evaluable (for at least one marker) 175 (121 patients) 
Male: female 3.9:1 (M=85, F=22) 
Median age 63yrs (38-75yrs) 
 
 
 
Source of tissue 
Lymph node 134 
Spleen 13 
Bone marrow 2 
Gut 8 
Other* 15 
Biopsies with blastoid morphology 30 
Diagnostic biopsies 48 
Median overall survival of cohort 3.4yrs 
Diagnostic biopsies with matched relapse biopsies 12 
*Tonsil, prostate, skin, paranasal sinuses, buccal mucosa, tongue 
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Western blotting 
Total protein for western blotting was extracted from cell lysates prepared at the indicated time-
points. Expression of p110α, PTEN, GAPDH, phosphorylated and total Syk, Akt and ribosomal S6 was 
evaluated by western blotting. Goat anti-human IgM F(a’b)2 fragments were used for BCR 
stimulation of the Jeko-1 cell line. 
 
ATP cytotoxicity assay 
Two cryopreserved primary MCL samples exhibiting loss of PTEN expression by western blotting 
were thawed in a water bath and re-suspended in growth medium prior to treatment with PI3K 
inhibitors in a 96 well plate. Cells were treated with increasing concentrations of the p110δ inhibitor 
GS-1101 (Active Biochem) alone and in combination with 1µM of the p110β inhibitor TGX-221 
(Selleck Chem). Following incubation for 72 hours, the ATP assay was performed to compare 
cytotoxicity of GS-1101 in these two samples with or without TGX-221. 
 
3.3 CLASS IA PI3K EXPRESSION IN MCL 
 
3.3.1 Expression in MCL compared to tonsil controls 
A total of 144 biopsies from 109 MCL patients were evaluable for all three isoforms. P110δ was 
consistently expressed at high levels in MCL. P110β expression was the weakest while p110α 
showed wide variation in expression across biopsies (Figure 3.1). Median expression of p110α 
(median IHC score=44.5 vs. 33.7, p=0.15) and p110δ (median IHC scores=77.4 vs. 81.1, p=0.2) in MCL 
was not significantly different from that seen in the germinal centers of tonsil controls whereas 
P110β expression was significantly lower in MCL (median IHC score=16.1 vs. 4.9, p=0.01). Appendix B 
contains a summary of the clinical details and IHC scores for individual samples.  
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Figure 3.1 Class Ia PI3K isoform expression in MCL Dot-plot showing expression of class IA PI3K isoforms in MCL biopsies in black (144 biopsies evaluable for 
all 3 isoforms from 109 patients) compared to tonsil controls in grey (n=14). Each dot for MCL samples represents the average IHC score of triplicate cores 
and lines represent median expression. (*= p<0.05) 
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3.3.2 Expression with MCL disease progression 
Based on the patient episode at which MCL biopsies were obtained, samples on the TMA were 
divided into those taken at diagnosis, 1st relapse and beyond 1st relapse. On comparing class Ia PI3K 
isoform expression between these groups, p110α expression was significantly higher in biopsies 
taken beyond first relapse compared to those taken at diagnosis (p=0.04) (Figure 3.2A). These 
differences were even more striking in sequential biopsies (p=0.008) with five out of six lymphoma 
samples showing significantly increased p110α expression beyond first relapse (Figure 3.2B). Images 
from two of the MCL sequential biopsy pairs with the greatest change between diagnosis and 1st 
relapse are shown in Figure 3.2C. Expression of p110α beyond first relapse was significantly higher 
than expression in tonsil controls (p=0.024). Neither p110β nor p110δ expression was altered 
significantly with relapse. (Figure 3.2 A, B) 
 
3.3.3 Expression in relation to morphology and Ki67 proliferation index 
Blastoid morphology was seen in 38 of 144 (26.4%) MCL biopsies. There was no significant difference 
in expression of any of the three class Ia isoforms between blastoid and non-blastoid MCL (Figure 
3.3A)  
 
Ki67 proliferative index was evaluated (using a cut off value of 30%167) in 30 diagnostic cases in the 
study cohort to determine its predictive value on disease specific survival. A significant survival 
benefit (p=0.0029, median survival 15.5mths vs 67.8mths) was observed in patients with Ki-67 
proliferation index <30% (Figure 3.3B). This cut-off was applied to both diagnostic and relapse 
biopsies to assess whether expression of any of the class Ia isoforms was positively associated with a 
higher proliferative index. Once again, no difference was seen in class Ia isoform expression between 
biopsies with high and low Ki67 expression (Figure 3.3C). 
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Figure 3.2 Class Ia PI3K isoform 
expression with MCL disease 
progression (A) Dot-plots showing a 
significant increase in p110α 
expression, but not p110β or p110δ, 
beyond first relapse. Bars represent 
median expression. (B) This pattern 
is more striking in 12 sequential 
cases (connected by grey lines), 6 of 
which had paired biopsies beyond 
first relapse. (C) IHC images (original 
magnification x200) of sequential 
biopsies from 2 patients showing 
significant increase in p110α 
expression beyond 1st relapse. Each 
dot represents the average IHC 
score of triplicate cores and bars 
represent median expression. (ns = 
not significant, *= p<0.05, 
**=p<0.01). 
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Figure 3.3 Class Ia PI3K isoform expression in relation to morphology and proliferative index (A) Dot 
plots showing no significant difference in class Ia isoform expression between blastoid and non-
blastoid morphology. Bars represent median expression. (B) Kaplan-Meier disease specific survival 
curves demonstrating a significantly worse survival in patients with a Ki-67 proliferation index of 
>30% at diagnosis (N=30). (C) Class Ia PI3K expression was compared between biopsies with high or 
low proliferation based on a Ki-67 cut-off of 30%. As shown in the dot-plots, no significant difference 
was found with any of the isoforms between these two groups. Each dot represents the average IHC 
score of triplicate cores and lines represent median expression.  
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3.4 EFFECT OF ISOFORM-SELECTIVE PI3K INHIBITION ON SIGNALLING IN MCL 
 
3.4.1 Granta519: A cell line with p110α over-expression 
The Granta519 cell line was established spontaneously from the peripheral blood of a 58 year old 
Caucasian lady who had an aggressive relapse within 6 months of achieving a response to 
combination chemotherapy (high dose cyclophosphamide and methotrexate, VP16, bleomycin, 
vincristine and prednisolone) for stage IV MCL.168 This cell line exhibits gene amplification of PIK3CA 
in relation to increased copy number144 (Figure 3.4A). In view of the previous report of PIK3CA gene 
amplification in MCL and the observation that p110α expression increases with MCL disease 
progression, the Granta519 MCL cell line was used to study the effect of isoform selective PI3K 
inhibition in this setting. 
 
Quantitative real-time PCR was used to confirm PIK3CA gene amplification in Granta519 by 
comparing it to the lymphoblastoid cell line NcNc. In keeping with this, western blotting 
demonstrated higher p110α expression in Granta519 compared to NcNc (Figure 3.4B). Next, the 
downstream effects of PI3K inhibition were compared between the p110δ inhibitor GS-1101 and a 
predominantly p110α and p110δ inhibitor GDC-0941, at a concentration of 1µM. Western blotting 
was performed 2 hours and 24 hours following treatment of Granta519 with the inhibitors. GS-1101 
treatment resulted in incomplete PI3K inhibition with residual Akt phosphorylation (thr308 and 
ser473) detectable at 2 hours and 24 hours.  At equimolar concentrations GDC-0941 blocked Akt 
phosphorylation in a sustained manner over 24 hours. This was reflected in reduced downstream 
phosphorylation of ribosomal S6 as a result of mTOR inhibition (Figure 3.4C). The relative reduction 
in phosphorylation of GSK-3β at both time-points was less striking between the two inhibitors. 
  
To establish whether or not the effect of GDC-0941 was related to its activity on the p110α isoform, 
GS-1101 was combined separately with the p110α inhibitor A66 and the p110β inhibitor TGX221.  
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These combinations were tested along with single agent GS-1101 and GDC-0941. All inhibitors were 
used at a concentration of 1µM. Further, Granta519 cells were serum-starved by incubating them in 
serum-free medium for 4 hours In order to assess the effects of these inhibitors on constitutive 
pathway activation. Combining GS-1101 with A66 had a similar effect as GDC-0941 whereas 
combining GS-1101 with TGX221 made no significant difference to residual Akt phosphorylation, 
confirming that residual constitutive PI3K signaling in GS-1101 treated cells was attributable to 
p110α activity. 
 
3.4.2 Effect on BCR signalling 
The Jeko-1 MCL cell line exhibits low or undetectable levels of p-Akt and was therefore used to study 
the effect of isoform selective inhibition on agonist-induced BCR signaling. Cells were pre-treated for 
an hour with 1µM isoform selective inhibitors prior to BCR stimulation with 10µg/ml goat anti-
human IgM F(a’b)2 fragments for 10 minutes. Western blotting at this point showed that whereas 
the p110δ inhibitor GS-1101 prevented phosphorylation of Akt (thr308) in response to BCR 
stimulation, the p110α inhibitor A66164 and the p110β inhibitor TGX221,117 had minimal effects on p-
Akt (thr308). Phosphorylation of Syk was used as a marker of BCR activation.  
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Figure 3.4 Downstream effects of isoform selective inhibition in the setting of PIK3CA over-
expression and agonistic BCR activation - (A) Fluorescent in situ hybridization images (from Psyrri et 
al, Clin Cancer Res 2009) demonstrating increased copy number of PIK3CA in Granta519 cells 
compared to Raji cells (green probe=PIK3CA, red probe=chromosome 3) (B) Real-time PCR and 
western blotting confirms increased expression of PIK3CA and p110α in Granta519 MCL cell lines 
compared to the lymphoblastoid cell line NcNc. (C) Western blot comparing downstream effects of 
GS-1101 (1μM) and GDC-0941 (1μM), at two time points demonstrating incomplete and non-
sustained effect of GS-1101 on p-Akt, p-S6 and to a lesser extent on p-GSK3β. (D) Western blot of 
serum-starved (4 hours) Granta519 cells treated with GS-1101, GDC-0941 and combinations of GS-
1101 with A66 or TGX-221 (all 1µM), for 2 hours, confirming the contribution of p110α to constitutive 
PI3K activation.(E) Effect of isoform-selective PI3K inhibition on IgM stimulated Jeko-1 cells. P-Syk 
(tyr525/526) was used as a marker of BCR activation. GS-1101 (p110δ-selective) blocked p-Akt 
production while A66 (p110α-selective) and TGX-221 (p110β-selective) did not.  
79 
 
3.5 LOSS OF PTEN EXPRESSION 
 
3.5.1 Immunohistochemistry 
PTEN protein expression was evaluated by IHC on the MCL TMAs. A PTEN null adenocarcinoma 
control was included with the TMAs during IHC staining to confirm there was no non-specific binding 
of the antibody (Figure 3.5A).  In keeping with previous reports,22,144 we found loss of PTEN 
expression in 17% of diagnostic (6/35) and 16% of all (22/138) biopsies. A higher proportion of 
tumours exhibiting blastoid morphology had loss of PTEN expression compared to cases with 
classical histology but this difference was not significant (20% vs. 15%, p=0.55 by Fisher’s exact test) 
(Figure 2C). No significant change was found in the pattern of isoform expression in biopsies that 
had loss of PTEN expression (Figure 2D).  
 
3.5.2 Loss of PTEN expression and p110β inhibition 
As both Granta519 and Jeko-1 had normal levels of PTEN protein expression, we probed 12 primary 
MCL samples (clinical information listed in table 4.1) for PTEN by western blotting and found loss of 
PTEN expression in 2 of 12 samples. A biopsy from one of the two samples was available on the TMA 
and confirmed the loss of PTEN expression. These two samples were treated with increasing 
concentrations of GS-1101, with or without the addition of 1µM of the p110β inhibitor TGX-221. The 
effect of these treatments at 72 hours was evaluated using an ATP cytotoxicity assay. No significant 
benefit was seen from the addition of TGX-221 to GS-1101 in either sample. 
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Figure 3.5 Loss of PTEN 
expression in MCL (A) Core from a 
PTEN null adenocarcinoma control 
showing PTEN negative tumor 
islands surrounded by PTEN 
positive stroma by IHC (original 
magnification x50 and x200). (B) 
Representative images of MCL 
cores with and without loss of 
PTEN expression (Original 
magnification x50 and x200). 
Macrophages and blood vessels 
were used as internal controls. (C) 
Bar graph of distribution of PTEN 
loss in blastoid and non-blastoid 
MCL. (D) Dot plot comparing class 
Ia isoform expression levels 
between cores with and without 
loss of PTEN expression showing 
no difference between the 3 
groups (PTEN-, PTEN 1+ and 
PTEN2+). Bars represent median 
expression. 
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Figure 3.6 Loss of PTEN expression and p110β inhibition (A) Western blot for PTEN expression in 
12 MCL primary samples showing loss of expression in 2 samples (indicated by arrows). (B) 
Results of ATP cytotoxicity assay after 72 hours treatment showing no benefit from addition of a 
p110β-selective inhibitor to GS-1101, compared to GS-1101 alone, in 2 MCL suspensions 
exhibiting loss of PTEN expression. 
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3.6 DISCUSSION 
 
These immunohistochemistry studies confirm that, similar to healthy B-cells, p110δ is the most 
abundant and consistently expressed class Ia PI3K isoform in MCL. The increase in p110α expression 
with disease progression that we observe has not previously been described. Psyrri et al 
demonstrated gene amplification of PIK3CA, related to increased copy number, in approximately 
two-thirds of cases evaluated but their study did not detail the treatment episode at which these 
samples were taken.144 The reason for p110α over-expression with disease progression is not clear. 
One theory could be that this over-expression contributes to MCL chemo-resistance with relapse. 
The mechanism may involve the expansion of a pre-existing clone of resistant tumour cells that have 
high p110α expression or induction of PIK3CA expression by cytotoxic agents. Interestingly there is 
evidence that prolonged activation of FOXO3a by doxorubicin can enhance survival in malignant cells 
through induction of PIK3CA expression. In the same study, increased FOXO3a induced expression of 
PIK3CA was found in chemo-resistant AML cell lines.130 
 
In relation to PI3K inhibition, we find that the p110δ inhibitor GS-1101 is unable to completely 
abolish constitutive activation of PI3K in a cell line with p110α over-expression and this residual PI3K 
activity is effectively abolished by addition of a p110α inhibitor. On the other hand, p110δ inhibition 
is sufficient to abolish BCR mediated activation of the PI3K pathway.  These observations, together 
with the immunohistochemistry findings, suggest an important role for additional p110α inhibition 
while confirming the importance of inhibiting the p110δ isoform in MCL. Of note, the p110α isoform 
has been shown to have a role in healthy BCR signalling.169 It has been demonstrated that while 
p110δ is the key isoform in agonist-induced BCR signalling, p110α contributes to agonist-
independent tonic BCR signalling. It is therefore possible that p110α over-expression increases the 
contribution of this isoform to agonist-independent PI3K signalling in MCL.  
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Similar to previous observations, we found loss of PTEN expression in approximately one-sixth (16%) 
of all MCL samples. Samples with loss of PTEN expression do not appear to have altered expression 
of class Ia isoforms. Addition of a p110β inhibitor to GS-1101 did not increase cytotoxicity in samples 
with loss of PTEN expression and, unlike reports in solid tumours, p110β does not appear to have an 
important role in this setting. However, this observation is limited to 2 samples and needs further 
study. Further, we only evaluated loss of PTEN expression as this was most relevant to the reports in 
solid tumours but, as discussed previously, other mechanisms of PTEN inactivation such as 
phosphorylation and micro RNA induced suppression have been described in MCL. 
 
In summary, while inhibition of p110δ is necessary, additional p110α inhibition appears to be 
required for effective PI3K inhibition in MCL, particularly with relapse. Further questions that arise 
from these observations are, firstly, whether the effects of dual p110α/δ inhibition on PI3K signalling 
translate into greater cytotoxicity in MCL cells and secondly, whether biomarkers defining patient 
subsets that are most likely to benefit from these inhibitors can be identified. The following chapter 
attempts to answer these questions. 
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CHAPTER 4: COMPARATIVE CYTOTOXICITY OF GS-1101 AND GDC-0941 IN 
MCL AND PREDICTORS OF SENSITIVITY 
 
 
 
4.1 INTRODUCTION  
 
Studies with PI3K inhibitors LY294002 and Wortmannin have demonstrated growth inhibition and, to 
a lesser degree, apoptosis in MCL cell lines and primary samples. 22,23,144 These chemical inhibitors 
have been used widely and have advanced our understanding of this pathway but are not selective 
at the concentrations at which PI3K inhibition is achieved.170 In recent years, a number of highly 
selective pan and isoform selective PI3K inhibitors have become available. GS-1101 was the first 
p110δ isoform-selective inhibitor to enter clinical trials and impressive activity was reported in early 
phase studies in patients with relapsed/refractory CLL and indolent NHL. The activity in 
relapsed/refractory MCL was less impressive.153  The inclusion of further targets in the PI3K pathway 
is therefore being explored in order to achieve better responses in MCL. Recent reports have 
described enhanced anti-proliferative effects in vitro by combining GS-1101 with an mTOR 
inhibitor171 or with a CDK4/CDK6 inhibitor172 in MCL. However, inclusion of a greater number of 
targets is likely to result in increased toxicity. This leads on to the need for biomarkers that can guide 
selection of patients in whom drugs with wider activity provide significantly greater benefit.  
 
In relation to PI3K inhibition itself, a reasonable assumption is that tumours with constitutive PI3K 
activation are the ones that are most likely to respond to PI3K inhibitors. Loss of PTEN expression 
and phosphorylation of Akt have been used widely as markers of PI3K pathway activation. Studies in 
pre-clinical models of breast cancer have validated PIK3CA mutations and amplification of epidermal 
growth factor receptor 2 as biomarkers for sensitivity to GDC-0941.173 More recently, the PIK3CA 
H1047R (exon 20) mutation has been described, in early phase studies in solid tumours, to be 
associated with greater sensitivity to PI3K/mTOR inhibition.174 Predictive biomarkers similar to those 
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described in solid tumours have not been described in lymphomas but two recent studies in 
haematological malignancies highlight the importance of biomarkers of resistance. The first 
demonstrates the association of the t(11;14) with resistance to  dual PI3K/mTOR inhibition in 
multiple myeloma175 whereas the second reveals the importance of NOTCH-MYC activation as a 
mechanism of resistance to dual PI3K/mTOR inhibition in T-acute lymphoblastic leukaemia (T-ALL).176  
 
In MCL, two separate studies have described a lack of activating mutations in exons 9 and 20 of 
PIK3CA.22,144 Somatic mutations of PIK3R1, the gene encoding the p85 regulatory subunit provides 
another mechanism of constitutive PI3K activation and their occurrence is associated with activation 
of all three class Ia isoforms. These have not been studied in MCL. Hotspots for somatic mutations in 
PIK3R1 have been described in exons 9, 10, 11, 13, 15 and 16.121  
 
Based on the findings discussed in the previous chapter, we compared the effect of the p110δ-
selective inhibitor GS-1101 with the predominantly p110α and p110δ selective inhibitor GDC-0941, 
on MCL cell proliferation and survival. In addition, the effect of the p110α inhibitor was studied in 
cell lines and primary samples. PTEN expression as well as phosphorylation of Akt was evaluated, 
gene expression of the class Ia isoforms was determined, samples were screened for PIK3CA and 
PIK3R1 mutations and finally the sensitivity of primary samples was studied in relation to these 
parameters. We found that a high PIK3CA/PIK3CD ratio was predictive of resistance of primary MCL 
cells to GS-1101 and that this ratio was significantly higher at relapse compared to diagnosis. In 
addition, mining of public gene expression profiling data revealed a significantly higher expression of 
PIK3CA in MCL compared to indolent NHL and CLL. Finally, we did not find increased expression of 
p110α with relapse in a study of sequential biopsies from follicular lymphoma patients, providing 
further evidence that the p110α isoform may have particular significance in MCL. 
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4.2 MATERIALS AND METHODS 
 
Cell lines and primary samples 
Two MCL cell lines (Jeko-1 and Granta519) and 12 primary MCL samples were used for initial studies 
of growth inhibition and cytotoxicity. An additional 10 primary MCL samples were used for validation 
of predictive markers identified in the experimental cohort. Table 4.1 lists the clinical details of 
primary samples used in these experiments.  
 
Cell proliferation and cytotoxicity assays 
MCL cells were incubated with increasing concentrations (0.1, 1, 5 and 10µM) of PI3K inhibitors GS-
1101, GDC-0941 or A66 and effects on growth and survival were measured at 72 hours. AnnexinV/PI 
and Guava ViaCount assays were used for cell lines while the ATP cytotoxicity assay was used for 
primary samples. The effect of GS-1101 and GDC-0941 on IL4 stimulated proliferation was measured 
by pre-treating cells with 20ng/ml IL4 before incubation for 72 hours with increasing concentrations 
of inhibitors. 
 
Western blotting 
Total protein for western blotting was extracted from cell lysates prepared at the indicated time-
points. Expression of Akt (phosphorylated thr308/ser473 and total), ribosomal S6 (phosphorylated 
ser235/236 and total), PTEN and GAPDH were evaluated by western blotting. Densitometry was 
performed using GelScan Standard software v5.1 (BioSciTec, Frankfurt, Germany). 
 
PIK3CA and PIK3R1 mutation analysis 
DNA was extracted from 20 primary MCL samples and 2 cell lines using the DNeasy mini kit (Qiagen). 
PCR, DNA purification and sequencing of exons 9 and 20 of PIK3CA and exons 9, 10, 11, 13, 15 and 16 
of PIK3R1 were performed as detailed in chapter 2.  
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Gene expression 
Total RNA was extracted from primary samples using the Qiagen RNeasy mini kit (Qiagen). Real-time 
quantitative PCR was performed using TaqMan gene expression assays Hs00192399_m1, 
Hs00927728_m1, Hs00180679_m1 and Hs99999905_m1 (Applied Biosystems) to determine gene 
expression of PIK3CA, PIK3CB, PIK3CD and GAPDH respectively in primary MCL samples and healthy 
controls. The ΔΔCt method was used for relative quantification of gene expression. Ct (cycle 
threshold) values for the class Ia isoforms were corrected to the endogenous control gene GAPDH by 
calculating the difference in thresholds values (ΔCt). The differences in ΔCt values between MCL 
samples and the calibrator (healthy controls) were then linearised to obtain relative gene expression 
values. These steps can be summarised as follows- 
 
ΔCt = CtISOFORM – CtGAPDH 
ΔΔCt = ΔCtMCL – ΔCtHEALTHY CONTROL 
Relative gene expression (fold change) = 2-ΔΔCt 
 
The PIK3CA/PIK3CD ratio was calculated by dividing the relative gene expression of PIK3CA with that 
of PIK3CD. This ratio always approximates 1 in the calibrator samples (healthy B-cells or tonsils) but 
does not reflect the true ratio in these samples. 
 
PIK3CA/PIK3CD = 2-ΔΔCt PIK3CA / 2-ΔΔCt PIK3CD 
 
Gene expression of class IA PI3K isoforms at diagnosis was compared between MCL and indolent 
NHL using publicly available affymetrix data (European Bioinformatics Institute www.ebi.ac.uk ref: E-
GEOD-16455) with the web-based software O-miner. P values were adjusted for multiple testing 
using the Benjamini-Hochberg correction and values <0.05 were considered significant.  
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Immunohistochemistry 
Sequential biopsies from 10 follicular lymphoma patients were studied using immunohistochemistry 
for p110α using methods identical to those used for MCL TMAs. Scoring of biopsies was done using 
the Ariol visual analysis software as previously described.  
 
Table 4.1 Characteristics of primary MCL samples used in PI3K inhibition studies 
Experimental cohort     
Sample Sex Source Nodal disease Blastoid Timing of sample 
M1 M PBMCs No Yes 1st relapse 
M2 M PBMCs Yes No Diagnosis 
M3 M PBMCs Yes Yes Diagnosis 
M5 F PBMCs Yes Yes Diagnosis 
M7 M PBMCs Yes No Diagnosis 
M8 M PBMCs Yes No Diagnosis 
M9 M PBMCs Yes No Diagnosis 
M11 M PBMCs No No Diagnosis 
M12 M Spleen Yes No Diagnosis 
M13 M PBMCs Yes No Diagnosis 
M16 M PBMCs Yes No Diagnosis 
M21 M Spleen Yes No Diagnosis 
Validation cohort     
Sample Sex Source Nodal disease Blastoid Timing of sample 
M10 M PBMCs Yes No Diagnosis 
M19 M PBMCs No No 1st relapse 
M23 M PBMCs Yes No Progression after Rx1 
M24 M PBMCs Yes No Diagnosis 
M25 M PBMCs Yes No Diagnosis 
M26 M BM Yes No Diagnosis 
M27 M BM Yes No Diagnosis 
M28 M PBMCs Yes No Diagnosis 
M29 M Spleen Yes No Diagnosis 
M30 F PBMCs Yes No 1st relapse 
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4.3 COMPARATIVE TOXICITY OF GS-1101 AND GDC-0941 
 
4.3.1 Cell lines 
Expression of the class Ia PI3K isoforms, PTEN and p-Akt (T308) by western blotting, in the 2 MCL cell 
lines Jeko-1 and Granta519 is shown in figure 4.1A. As mentioned previously, Jeko-1 had very low 
levels of basal Akt phosphorylation compared to Granta519. PTEN expression was intact in both cell 
lines and class Ia isoform expression was similar. Growth inhibition and cytotoxicity were 
determined in both cell lines using the Guava ViaCount and Annexin-V/PI assays respectively. GDC-
0941 induced significant reduction in the viable cell number in Granta519 and Jeko-1 compared to 
both GS-1101 and the p110α selective inhibitor A66 (Figure 4.1 B). GDC-0941 also induced significant 
apoptosis in the Jeko-1 cell line, but only at concentrations >5µM, as demonstrated in figures 4.1C 
and D, while GS-1101 induced minimal apoptosis in both cell lines. 
 
4.3.2 Primary samples 
Western blotting was performed on 12 primary samples (‘experimental cohort’ in Table 4.1) to 
determine basal expression of p-Akt and PTEN. Samples were treated with increasing concentrations 
of GS-1101 and GDC-0941. Cytotoxicity was measured using the ATP assay at 72 hours. Variability 
was observed in the sensitivity of individual samples but overall the activity of GDC-0941 was 
significantly greater than that of GS-1101 starting at a concentration of 0.1μM (Figure 4.2A). Similar 
to observations in the two cell lines, PTEN expression and phosphorylation of Akt (Figure 4.2B) did 
not predict response to either inhibitor in primary samples. In addition, some primary samples were 
resistant to both GS-1101 and GDC-0941. The effect of these two drugs on individual primary 
samples is detailed later in this chapter. 
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Figure 4.1 Activity of GS-1101, A66 and GDC-0941 on MCL cell lines. (A) Western blot showing 
basal expression of p-Akt (thr308), PTEN and class Ia PI3K isoforms in Jeko-1 and Granta519. (B) 
Significantly greater growth inhibition seen using the Guava Viacount assay in both cell lines with 
GDC-0941 compared to both GS-1101 and A66. (C) The effect of both GS-1101 and GDC-0941 on 
apoptosis using flow cytometry with Annexin-V/PI staining is minimal although significant 
apoptosis is seen on treating Jeko-1 with >5µM GDC-0941. (D) Representative flow cytometry 
plots of AnnexinV/PI uptake in Granta519 and Jeko-1 cells treated with GDC-0941. Error bars 
represent standard deviation of three separate experiments. 
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4.3.3 IL4 stimulated proliferation of MCL cells 
The activity of GS-1101 and GDC-0941 was compared at 72 hours using the ATP cytotoxicity assay, in 
3 primary MCL samples stimulated with IL4 (Figure 4.2C). Increase in ATP luminescence reflecting 
proliferation was seen in IL4 stimulated, untreated controls from all 3 samples. GDC-0941 appeared 
to be more cytotoxic than GS-1101 at all concentrations (means: 0.1µM=152.7 vs 132.7, 1µM=136.3 
vs 106, 5µM=111 vs 89, 10µM=89.67 vs 71) in the presence of IL4 although these differences were 
not significant using an unpaired t-test. The difference in the degree of IL4 stimulated proliferation 
between untreated controls in the two groups was also not significant but mean proliferation was 
higher in the GS-1101 group (198.7 vs 175.7). This made it difficult to draw comparisons between 
the activity of the two inhibitors in the presence of IL4 but overall both appeared to counteract IL4 
induced proliferation to a similar degree. 
 
4.3.4 Healthy B-cells 
The effect of GS-1101 and GDC-0941, at the concentrations used in MCL cells, was evaluated in B-
cells isolated from healthy PBMCs. At 72 hours, GDC-0941 appeared to be more cytotoxic compared 
to GS-1101 but this was not statistically significant at any of the concentrations evaluated (Figure 
4.2D). 
 
4.4 BIOMARKERS PREDICTIVE OF RESISTANCE TO GS-1101 
 
As would be expected, samples that were responsive to PI3K inhibition with GS-1101 showed similar 
sensitivity to treatment with GDC-0941. As sensitivity is relative and difficult to define, we elected to 
evaluate the parameters described below against their ability to predict resistance to GS-1101. 
Markers were evaluated in relation to the effect of the two drugs at 0.1 and 1µM, concentrations at 
which they are most likely to be faithful to their targets. 
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Figure 4.2 Activity of GS-1101 and GDC-0941 
in primary MCL. (A) Dot plots showing greater 
cytotoxicity in the ATP assay with GDC-0941 
compared to GS-1101 in 12 primary MCL 
samples with statistically significant toxicity at 
and above 0.1µM. Lines represent median 
viable cell number (B) Activity of GS-1101 and 
GDC-0941 on IL4 stimulated proliferation in 3 
primary MCL samples. Lines represent mean 
viable cell number. (C) Activity of GS-1101 and 
GDC-0941 in healthy B-cell controls (n=3). 
Error bars represent standard deviation of 3 
separate experiments. 
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4.4.1 PTEN and phosphorylation of downstream targets  
Loss of PTEN expression did not predict sensitivity to either inhibitor. While samples M3 and M16 
were minimally responsive to GS-1101 (figure 3.6), sample M16 was significantly more sensitive to 
GDC-0941. The two primary samples with the strongest basal phosphorylation of Akt (thr308) were 
M5 and M9. While both GS-1101 and GDC-0941 had minimal activity against M5, sample M9 
appeared to be equally responsive to both drugs. Another primary sample M7 was equally 
responsive to both drugs but had weak phosphorylation of Akt. This is in keeping with the findings in 
the two cell lines where despite differences in basal phosphorylation of Akt both cell lines had 
similar responses to GS-1101 and GDC-0941. 
 
Downstream phosphorylation of Akt and ribosomal S6 was evaluated in Jeko-1 and Granta519, as 
well as two primary samples (M8 and M9). In cell lines, downstream effects were evaluated at 2 
hours and 24 hours, comparing effects of GS-1101 and GDC-0941 (Figure 4.4A). In Granta519, as 
described previously, PI3K inhibition with the p110α/δ inhibitor GDC-0941 resulted in more effective 
and sustained inhibition of Akt phosphorylation compared to p110δ selective inhibition with GS-
1101. This was reflected in decreased downstream phosphorylation of p-S6. In the Jeko-1 cell line, 
basal phosphorylation of Akt was not detected and therefore could not be used to as a marker of 
PI3K inhibition. However, a decrease in phosphorylation of S6 was seen in a similar pattern to that 
seen with Granta519 and GDC-0941 treatment resulted in sustained inhibition of p-S6.  
 
On evaluation with the ATP assay at 72 hours, primary sample M8 was relatively resistant to both 
GS-1101 and GDC-0941 while both inhibitors were found to induce significantly greater toxicity in 
primary sample M9. Interestingly, there was very little difference in the downstream effects of PI3K 
inhibition in both primary samples at the 2 hour time point and equal, near complete inhibition of 
Akt (thr308) and S6 phosphorylation was seen with both GS-1101 and GDC-0941. In sample M8, 
some residual phosphorylation of ribosomal S6 was observed in cells treated with GS-1101 
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compared to those treated with GDC-0941, but the cytotoxic effect of both drugs on M8 was 
minimal (Figure 4.4B). Due to limited cell numbers, western blots were not performed on primary 
samples at 24 hours. 
 
 
 
 
  M1        M2      M3      M5       M7       M8     M9      M11    M12     M13    M16      M21
A.
B.
 
Figure 4.3 Correlation of p-Akt (t308) and PTEN with response to GS-1101 and GDC-0941 in primary 
samples. (A) Western blot showing expression levels of p-Akt (t308) and PTEN in 12 primary samples. 
(B) Comparative activity of GS-1101 and GDC-0941 determined by the ATP assay. The X axis shows the 
viable cell number as a percentage of the untreated control. Error bars represent standard deviation 
of triplicates in the same experiment. 
95 
 
 
 
 
 
 
A.
B.
Granta519 Jeko-1
2 hours 24 hours 2 hours                          24 hours
GS-1101
GDC-0941
p-Akt (thr308)
Total Akt
p-S6 (s235/236)
GAPDH
-
-
-
-
 
 
 
 
 
 
Figure 4.4 Comparative effects of GS-1101 and GDC-0941 on downstream targets of PI3K. (A) 
Western blots displaying downstream effects of GS-1101 and GDC-0941 in cell lines Granta519 
and Jeko-1 at two time points 2 and 24 hours.  The immunoblot for Granta519 is the same as 
shown in figure 3.4C. (B) Western blot displaying downstream effects of GS-1101 and GDC-
0941 in 2 primary MCL samples at 2 hours. There is no marked difference between 
downstream effects even though sample M8 is resistant to both inhibitors while sample M9 is 
sensitive to both. 
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4.4.2 PIK3CA and PIK3R1 mutations 
DNA extracted from 2 MCL cell lines (Jeko-1 and Granta519) and 20 primary MCL samples was 
sequenced and screened for somatic mutations in the hotspot regions of PIK3CA (exons 9 and 20) 
and PIK3R1 (exons 9, 10, 11, 13, 15 and 16). 12 of the 20 primary DNA samples screened were those 
in the experimental cohort while the remaining 8 DNA samples were obtained from diagnosis-
relapse frozen biopsy pairs form 4 patients (clinical information for these samples can be found in 
figure 4.8). No mutations were detected suggesting that somatic mutations in class Ia PI3Ks leading 
to their constitutive activation are rare or absent in MCL. 
 
4.4.3 Gene expression of class Ia isoforms and the PIK3CA/PIK3CD ratio 
Relative gene expression of class Ia isoforms was determined by qRT-PCR on RNA extracted from 12 
primary MCL samples (experimental cohort). In keeping with findings at the protein level, PIK3CD 
gene expression was the highest while PIK3CB gene expression was the weakest (Figure 4.5A). 
Compared to healthy B-cell controls, gene expression of isoforms PIK3CA and PIK3CD showed 
significant up-regulation (p=0.0115 for both using the Mann-Whitney test) in primary MCL samples.  
 
When evaluated independently, relative gene expression (2-ΔΔCt) of neither PIK3CA nor PIK3CD was 
able to predict resistance to GS-1101. In order to evaluate the importance of the relative 
contribution of these two isoforms, the ratio of their gene expression (PIK3CA/PIK3CD) was 
calculated. This ratio separated samples into two groups, one with ratios similar to that seen in 
healthy B-cell controls and another group with significantly higher expression (Figure 4.5B). 
PIK3CA/PIK3CD greater than twice the mean ratio in healthy B-cell controls identified a group of 
samples that were resistant to GS-1101 and showed a significantly greater response to GDC-0941 
(p=0.03 at 0.1µM, p=0.008 at 1µM) (Figure 4.5B). The two samples that were most sensitive to GS-
1101 reassuringly fell in the group with the lower ratios. These differences were seen at 0.1 and 
1µM, concentrations at which these inhibitors are likely to be selective for their isoform targets. 
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Figure 4.5 Gene expression of class Ia isoforms and predictive value of the PIK3CA/PIK3CD ratio. 
(A) Gene expression of class Ia isoforms in healthy B-cells (grey bars) compared to expression in 
MCL (black bars). (B) A PIK3CA/PIK3CD ratio greater than twice that the mean ratio in healthy B-
cells (dotted line) can identify primary samples that are resistant to GS-1101 but significantly more 
sensitive to GDC-0941. Bars represent median expression. The accompanying table displays the 
PIK3CA/PIK3CD values for each of the samples.  
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An independent cohort of 10 primary MCL samples (Table 4.1) was used to validate these findings. 
RNA was extracted from these samples and qRT-PCR was performed together with RNA from three 
healthy B-cell controls. Relative gene expression of the class Ia isoforms was calculated and the 
PIK3CA/PIK3CD ratio was determined using the same methods as for the experimental cohort 
(Figure 4.6A). 
 
Alongside the qRT-PCR studies, samples in the validation cohort were incubated with 1µM of GS-
1101 or GDC-0941 and ATP luminescence was measured at 72 hours. Samples were also treated with 
1µM A66 to determine the effect of p110α selective inhibition (Figure 4.6B). On plotting the ratios, 
the primary samples did not separate as distinctly as with the experimental cohort but on applying 
the cut-off ( 2 x mean ratio in healthy B-cells) once again samples above the cut-off were found to be 
resistant to GS-1101 but significantly more sensitive to GDC-0941 (p=0.0079). As with the 
experimental cohort, primary samples that were relatively sensitive to GS-1101 fell in the group of 
samples with low PIK3CA/PIK3CD ratios. P110α selective inhibition with A66 did not have a 
significant effect on any of the samples treated. 
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Figure 4.6 Validation of the PIK3CA/PIK3CD ratio as a predictor of resistance to GS-1101. (A) 
Validation of PIK3CA/PIK3CD ratio in an independent cohort of 10 MCL primary samples. Dot 
plot showing PIK3CA/PIK3CD ratios with a cut-off set at twice the ratio in healthy B-cell controls 
(dotted line). The accompanying table displays PIK3CA/PIK3CD values for each of the samples. 
Samples with a high ratio (black dots) are significantly more sensitive to GDC-0941 compared to 
GS-1101 while those with lower ratios have a similar sensitivity to both drugs. Lines represent 
median percentage viable cell number. (B) Bar graph comparing activity of GS-1101, GDC-0941 
and A66 in the validation cohort. Error bars represent standard deviation of triplicate samples 
in the same experiment. 
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4.5 GENE EXPRESSION IN SEQUENTIAL MCL BIOPSIES  
 
Quantitative RT-PCR was used to determine gene expression of class Ia isoforms in frozen sequential 
biopsies that were available in the tissue bank from four MCL patients. Complementary DNA derived 
from two tonsil controls was incorporated in the same run. Protein was extracted simultaneously to 
determine expression of isoforms by western blotting. These were the only frozen sequential MCL 
biopsies available and, unfortunately, were mutually exclusive from the sequential biopsies studied 
by IHC.  
 
As would be expected, PIK3CD expression was the strongest in MCL samples but was also found to 
be up-regulated compared to expression in tonsil controls (Figure 4.7A). However, p110δ expression 
was comparable between tonsils and MCL samples by western blotting.  Gene and protein 
expression of PIK3CB were the weakest among the three isoforms. Gene expression of PIK3CA was 
also weak but expression was significantly higher than tonsil controls (Figure 4.7B). This was 
reflected in protein expression of p110α on western blotting (Figure 4.7C).  
 
Increase in p110α expression was seen with relapse in 2 out of 4 sequential biopsies by western 
blotting (Figure 4.7B). PIK3CA expression was also seen to increase in the same two biopsies with 
relapse (Figure 4.7C). Interestingly, on evaluating the ratio of PIK3CA to PIK3CD, we found that all 4 
sequential biopsies showed a marked increase in the PIK3CA/PIK3CD ratio with relapse, relative to 
both diagnostic biopsies and tonsil controls (Figure 4.7D).  Densitometry was performed on 
immunoblots of p110α and p110δ and corrected to densitometry of GAPDH (loading control). 
Although the ratios of p110α to p110δ showed wide variation, an increase with relapse was 
observed in all 4 cases, similar to that seen with gene expression (Figure 4.7E). Figure 4.8 indicates 
the timing of the biopsies in patients S1 to S4 in relation to disease course and treatment received.
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Figure 4.7 Gene expression and PIK3CA/PIK3CD ratio in sequential 
MCL biopsies (A) Gene expression of class Ia isoforms. Tonsil controls 
are in grey and sequential samples from the same patient share the 
same colour. Individual patients are represented as S1-S4 while the 
accompanying letter indicates timing of the biopsy for e.g. D indicates 
a biopsy at diagnosis, R1 at 1st relapse and so on. (B) Fold change in 
PIK3CA expression (2-ΔΔCt) in MCL samples compared to tonsil 
controls. (C) Immunoblot of class Ia isoforms in tonsils and MCL. (D) 
Marked increase in PIK3CA/PIK3CD ratio in biopsies taken at relapse 
compared to diagnostic biopsies and tonsil controls. (E) Table 
displaying densitometry values for p110α and p110δ as well as the 
p110α/ p110δ ratio showing a similar trend. 
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Figure 4.8 Graphical representation of the timing of biopsies in relation to disease course and treatment received in patients S1-S4.  
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4.6 EXPRESSION OF CLASS IA ISOFORMS IN INDOLENT NHL 
 
4.6.1 Data mining of public gene expression profiling data  
In order to investigate whether differences existed in isoform expression between MCL and other 
NHL, we extracted PI3K class IA isoform expression from public gene expression profiling data 
(www.ebi.ac.uk) that was available from a study comparing diagnostic samples of MCL to indolent 
NHL (Figure 4.8A)177 and analyse this data using the O-miner software.178 Even in these samples, 
median expression of the PIK3CA isoform was significantly higher in MCL (n=15) compared to CLL 
(n=17), hairy cell leukaemia (n=5), splenic marginal zone lymphoma (n=4) and follicular lymphoma 
(n=7). This difference was not seen with PIK3CB or PIK3CD implying that the PIK3CA/PIK3CD ratio 
was higher in MCL than in CLL and indolent NHL. Benjamini-Hochberg multiple testing adjusted p 
values were as follows cMCL vs HCL=0.005, cMCL vs SMZL=0.0001 cMCL vs CLL=0.003 and cMCl vs 
FL= 0.05. There was no publicly available data comparing gene expression in relapsed lymphomas 
that we could analyze at the time of this study.  
 
4.6.2 Follicular lymphoma sequential biopsies 
Immunohistochemistry for p110α was performed in sequential biopsies from ten follicular 
lymphoma patients, four of whom had paired biopsies beyond first relapse. Sections were stained as 
for the MCL tissue microarray and were scanned and scored with the same protocols using the Ariol 
visual analysis software. There was no evidence of increase in p110α expression with relapse and in 
fact a decrease in expression was observed with progression in some sequential biopsies (Figure 
4.8B, C). 
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Figure 4.9 Gene expression of PIK3CA in MCL 
compared to indolent NHL and p110α 
expression in sequential biopsies of follicular 
lymphoma. (A) Gene expression of class IA PI3K 
isoforms at diagnosis in MCL was compared with 
indolent NHL. cMCL=conventional MCL, 
HCL=hairy cell leukemia, SMZL= splenic marginal 
zone lymphoma, CLL=chronic lymphocytic 
leukemia, FL=follicular lymphoma. (B) IHC images 
of 4 follicular lymphoma diagnosis-second 
relapse pairs showing no increase in p110α 
expression with relapse (original magnification 
x200). (C) Dot-plot comparing expression of 
p110α in sequential biopsies from follicular 
lymphoma patients (n=10). No evidence of 
increased p110α expression is seen with relapse. 
Pairs are connected by straight lines. 
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4.7 DISCUSSION 
 
Dual inhibition of p110α and p110δ with GDC-0941 appears to result not only in more effective PI3K 
inhibition in MCL but also greater cytotoxicity towards MCL cells. These findings are unlikely to be 
influenced by p110γ, the only class IB catalytic unit isoform, as both GS-1101 and GDC-0941 have 
similar efficacy against p110γ. However, it is also important to note that some primary MCL samples 
showed similar sensitivity (or resistance) to GS-1101 and GDC-0941. In addition, these experiments 
show that GS-1101 was able to counteract IL4 induced proliferation in three primary MCL samples as 
effectively as GDC-0941. This finding highlights the importance of p110δ in IL4 stimulated 
proliferation of MCL cells and this may be similar to the importance of this isoform in BCR signalling. 
These findings appear to be consistent with the role of p110δ described in healthy B-cells.140  
 
In both cell lines and primary samples, neither the degree of constitutive Akt phosphorylation nor 
PTEN status predicted resistance to GS-1101. Another interesting observation, although evaluated 
only in one primary sample, was that while effective inhibition of Akt appeared to be necessary, it 
did not necessarily predict cytotoxicity.  This could be explained by activation of alternative 
pathways that may enable cells to survive despite PI3K inhibition. Activation of NOTCH signalling 
may be one such mechanism as shown in studies in T-ALL176 and indeed NOTCH mutations are found 
in approximately 12% of MCL27 suggesting an important role for this pathway.  
 
It is reasonable to assume that inhibition of a greater number of target kinases is likely to result in 
greater toxicity with clinical use. In the experiments above, the difference in the in vitro toxicity of 
GDC-0941 and GS-1101 towards healthy B-cells is not statistically significant but appears to be 
slightly greater with GDC-0941. The important issue of course is the effect of p110α inhibition on 
non-haematopoietic tissues. Early phase trials with GDC-0941 have reported a favourable toxicity 
profile below a dose of 450mg QD in advanced solid tumour patients with activity seen starting at 
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100mg. Side effects were related to gastro-intestinal (GI) toxicity and a few grade 3-4 adverse events 
including fatigue, neutropenia and hyperglycemia were seen with higher doses (130mg and 
above).154  On the other hand, hyperglycemia is not reported as a side-effect with GS-1101 although 
fatigue, GI side-effects and a reversible rise in ALT and AST have been reported.153  
 
The PIK3CA/PIK3CD ratio appears to be a useful and reproducible marker in our in vitro studies. 
Primary samples with a high PIK3CA/PIK3CD ratio are resistant to inhibition with GS-1101 but also 
show significantly greater sensitivity to GDC-0941. A high ratio is therefore likely to identify tumors 
that can utilize p110α mediated constitutive PI3K signalling for survival and can maintain PI3K 
signalling despite p110δ inhibition. Interestingly, the PIK3CA/PIK3CD ratio was up-regulated with 
progression in all 4 sequential biopsies that were studied perhaps reflecting increased constitutive 
signalling through p110α with disease progression in MCL. The rise in PIK3CA with relapse, in 
conjunction with the proposed role of PIK3CA in mediating chemo-resistance130 emphasize the 
potential benefit of targeting this isoform in MCL.  
 
The MCL cell suspensions used in these studies were selected based on their viability and cell 
number rather than their source. The fact that the majority of primary samples used in these studies 
were derived from the peripheral blood of MCL patients at diagnosis Is a potential limitation as 
isolated leukaemic disease is considered a favourable prognostic factor in MCL and therefore these 
samples may represent a less aggressive cohort. However, it is also important to note that the 
majority of these patients had accompanying nodal disease (Table 4.1). 
 
Another finding in these studies is that while Akt phosphorylation is a useful marker to study 
responses to PI3K inhibition the degree of phosphorylation does not predict sensitivity to PI3K 
inhibition and cells lacking constitutive Akt phosphorylation can still be responsive to PI3K inhibition. 
We find that constitutive Akt phosphorylation is not always seen in primary MCL exhibiting increased 
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PIK3CA/PIK3CD. This is not entirely surprising as Akt independent PI3K signalling has been found in 
cancers harboring PIK3CA mutations and similar mechanisms could operate in MCL exhibiting a high 
PIK3CA/PIK3CD ratio. 
 
Finally, an important finding in relation to the background to these studies is the significantly higher 
gene expression of PIK3CA in MCL compared to CLL and other indolent NHL. This indirectly implies a 
higher PIK3CA/PIK3CD ratio in MCL as PIK3CB and PIK3CD expression are not significantly different in 
MCL compared to CLL and indolent NHL. Although it would be interesting to further explore the 
PIK3CA/PIK3CD ratio and sensitivity to isoform selective inhibitors in other indolent NHL, these 
studies would not have been possible to complete within the time frame for this research. However, 
in support of the theory that this phenomenon may be peculiar to MCL, we did not find an increase 
in p110α with relapse using immunohistochemistry on 10 sequential follicular lymphoma biopsies.  
 
In summary, PIK3CA may be of particular significance in MCL, a disease characterized by frequent 
relapse and chemo-resistance. These studies highlight the potential benefit of dual p110α/δ 
inhibition, particularly in MCL exhibiting a high PIK3CA/PIK3CD ratio, but require confirmation in 
vivo. While PIK3CA may or may not be important in other lymphomas, these findings along with the 
discrepant results of early phase studies in relapsed/refractory MCL, compared to other NHL, 
suggest that dual inhibition of p110α and p110δ should be explored as a therapeutic option in MCL.  
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CHAPTER 5: ESTABLISHING A DISSEMINATED XENOGRAFT MODEL OF HUMAN 
PRIMARY MANTLE CELL LYMPHOMA IN NSG MICE 
 
 
5.1 INTRODUCTION  
 
The initial intention of carrying out xenograft studies as part of this research was to establish a 
model to validate our findings in vivo. As the Haemato-Oncology department had well established 
links with the Haematopoietic stem cell laboratory (London Research Institute, Cancer Research UK, 
Lincoln’s Inn Fields) led by Dr Dominique Bonnet, a collaboration was set up to use their experience 
with NSG mice to establish a disseminated MCL mouse model. Subcutaneous or disseminated 
models of MCL cell lines in immunodeficient mice (SCID, NOD-SCID and NSG) are relatively easy to 
establish and have been widely employed for in vivo studies. However, these models have their 
limitations which include problems inherent to cell lines such as genetic instability and 
contamination, rapid progression of disease in mice and the difficulty in interpreting interactions 
with the microenvironment. The relatively large collection of MCL cell suspensions available in the 
tissue bank at Barts Cancer Institute led us to shift our focus to the possibility of establishing a NSG 
model of human primary MCL. The only primary human MCL mouse model described in the 
literature was established by injection of CD19 selected primary MCL cells into human embryonic 
bone grafts that were implanted subcutaneously in SCID mice (SCID-Hu). As SCID mice without 
subcutaneous human embryonic bone grafts did not show engraftment, the study concluded that a 
human bone marrow microenvironment was necessary for establishing MCL in SCID mice. However, 
access to the NSG model which allows engraftment of a wider range of primary human 
haematopoietic cells and the recent report of an NSG model of human primary CLL provided 
encouragement for our hypothesis.179 The SCID-Hu model requires access to human embryonic bone 
grafts and therefore a primary human MCL xenograft NSG model, if viable, can provide a more easily 
reproducible model for both pre-clinical drug testing and in vivo studies of MCL biology. 
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Prior to undertaking studies with primary cells, we injected two concentrations of the Jeko-1 cell line 
into NSG mice to study the kinetics and homing of these cells with bioluminescent imaging. This was 
done in order to guide follow up of mice injected with primary cells. 
 
5.2 MATERIALS AND METHODS 
 
All animal experiments were performed in line with home office as well as CRUK guidelines, and 
under the home office license held by Dr Dominique Bonnet’s Haematopoietic stem cell laboratory 
at the CRUK laboratories, Lincoln’s Inn Fields. As mentioned in chapter 2, luciferase transduction of 
Jeko-1 cells, tail vein injection of cells into mice, bioluminescent imaging and flow cytometry on 
mouse derived cells were performed by Linda Ariza-McNaughton at the Haematopoeitic stem cell 
laboratory, CRUK at Lincoln’s Inn Fields while characterisation/preparation of primary samples, 
immunohistochemistry on mouse derived tissue and processing of mouse spleens was done by me 
with assistance from Andrew Clear, Debra Lillington and Amy Roe at Barts Cancer Institute. 
 
5.2.1 Luciferase transduction of the Jeko-1 cell line 
The firefly luciferase gene encodes a 61KDa luciferase enzyme that converts D-lucifern to 
oxyluciferin in the presence of ATP, releasing light in the process. Quantification of this luminescence 
can be used as a reflection of cell number (as in the ATP cytotoxicity assay) or tumour burden in 
mice through bioluminescent imaging. As previously mentioned, the identity of the Jeko-1 cell line 
was confirmed by STR typing. Jeko-1 cells were transduced with a lentiviral vector expressing a 
double fusion reporter gene – green fluorescent protein (GFP) and firefly luciferase. This was 
followed by flow assisted sorting of GFP positive cells and injection of either 5x105 or 2x106 cells (in 
200μlPBS + 2%FCS) by tail-vein into pre-irradiated NSG mice. Kinetics, disease burden and 
distribution were assessed by non-invasive bioluminescence imaging (BLI) following injection of D-
luciferin. 
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5.2.2 Bioluminescent imaging 
In vivo optical imaging was performed at 7, 14, 21 and 28 days using IVIS Spectrum bioluminescence- 
fluorescence optical imaging system (Caliper Life Science, Runcorn, UK). Before imaging, 125 mg/kg 
D-luciferin (Caliper Life Science) was administered intra-peritoneally to each mouse. Isoflurane (3%) 
was used to induce general anaesthesia and mice were placed in a light-tight heated chamber. After 
acquiring bright-field images of each mouse, anterior and posterior luminescent images were then 
successively acquired with 1- to 5-min exposure time. Optical images were displayed and analyzed 
with the IVIS Living Image software (Caliper Life Science). Regions of interest (ROI) were drawn 
manually around the bodies of the mice to assess the emitted signal intensity and sum of the 
anterior and posterior measurements were used as the total bioluminescence signal for each mouse.  
 
5.2.3 Characterisation and preparation of primary samples 
The Haemato-Oncology tissue bank at Barts Cancer Institute has a well established collection of MCL 
single cell suspensions, collected following informed consent from patients at diagnosis and/or 
relapse, which are linked to a clinical information database. At present, there are over 100 MCL 
patient samples in cell suspensions prepared from peripheral blood, lymph nodes, spleen and bone 
marrow that are cryopreserved in liquid nitrogen and can be accessed through a sample requisition 
process. The three samples that were used in our experiments (Table 5.1)were selected as each had 
over 50 cryopreserved vials available per patient episode containing approximately 5-10x107 cells 
per vial with good viability (>80%) on thawing. These were chosen to ensure we could test our 
hypothesis with sufficient replicates.  
 
Following thawing, samples were characterised by flow cytometry for CD5/CD20 positive tumour 
cells and T-cell content (as described in chapter 2). Samples were also confirmed to have the IGH: 
CCND1 translocation by FISH. A total of 4 x 107 T-cell depleted cells (107 per mouse) were re-
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suspended in 800μl sterile PBS containing 2% FCS and transported on ice to the animal facility at 
Lincoln’s Inn Fields for tail-vein injection into pre-irradiated NSG mice. 
 
Table 5.1 Details of primary MCL samples injected into NSG mice 
 Source  Timing  Morphology  t(11;14)  Viability 
Primary1  PBMCs  1st relapse  Blastoid  Yes  96.5% 
Primary2  PBMCs  Diagnosis  Blastoid  Yes  96.7% 
Primary3  Lymph node cell suspension  2nd relapse  Classical  Yes  88.1% 
 
 
T-cell depletion: T-cell depletion was performed using magnetic depletion with CD3 micro beads 
(Miltenyi Biotec) to obtain an untouched T-cell depleted population. Briefly, a cell count was 
performed before centrifuging cells at 400xg for 10 minutes and re-suspending them in 80μl of 
MACS buffer per 107 cells. 20μl of CD3 beads were then added for every 107 cells and the suspension 
was mixed well before incubation on ice for 15 minutes. Following this cells were washed with 1-2ml 
of MACS buffer per 107 cells and up to 108 cells were re-suspended in 500μl MACS buffer. LD 
columns (Miltenyi Biotec) were prepared in the magnetic field of a MACS separator (Miltenyi Biotec) 
by rinsing with 2ml of buffer. Cell suspensions were applied to the columns and columns were 
washed through with 2 x 1ml MACS buffer. The effluent containing the CD3 depleted fraction was 
collected and cell counts were performed. CD3 depletion was confirmed by flow cytometry. 4 x 107 
T-cell depleted cells were re-suspended in 800μl of PBS + 2%FCS for injection into mice. 
 
Fluorescent in situ hybridisation (FISH): FISH for the IGH: CCNDI translocation was performed at the 
cytogenetics laboratory at Barts Health NHS Trust. 5-10 x107 MCL cells were thawed and re-
suspended in cytogenetics medium for interphase FISH analysis using the Vysis LSI IGH/CCND1 XT 
Dual Color, Dual Fusion Translocation Probe (Abbott Laboratories, Abbott Park, Illinois, USA). 
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5.2.4 Preparation and injection of NSG mice 
Eight to twelve week old NSG mice were γ-irradiated (3.75 Gy) within 24 hours of tail vein injection 
with T-cell depleted PBMCs. The recently described NSG models of human CLL were established by 
injecting 5-10x107 cells per mouse. We injected 107 cells per mouse (4 mice in each group) with a 
view to increasing cell numbers if we failed to see engraftment. 
 
5.2.5 Monitoring of mice 
Flow cytometry:  Fluorochrome conjugated antibodies anti-human CD45-PerCP, anti-human CD33-
APC, anti-human CD20-PE and anti-human CD5-PECy7 were purchased from BD biosciences while 
anti-mouse CD45-FITC was purchased from e-Bioscience (San Diego, CA, USA). Mice were bled at 3-4 
weeks and then again at 10-12 weeks after injection of cells. Flow cytometric analysis was 
performed using DAPI staining for live/dead discrimination. Cells were then evaluated for mouse 
CD45 (mCD45) and human CD45 (hCD45) after which hCD45 gated cells were evaluated for hCD3, 
hCD5 and hCD20 positivity. Cells flushed out from bone marrow of mice at sacrifice were evaluated 
in the same manner. Analysis was performed on FlowJo software version 8.8.7 (TreeStar Inc, 
Ashland, OR, USA). 
 
Immunohistochemistry: Mice were sacrificed at 20 weeks and dissection was carried out to look for 
evidence of gross organ involvement. Spleen, liver, bone marrow, ileo-caecal junction and any other 
organs that appeared affected were harvested and fixed in formalin. In addition, portions from the 
harvested spleens were placed in ice-cold PBS + 2% FCS for preparing cell suspensions.  Home office 
criteria were used to judge if mice need to be sacrificed at any point before this. FFPE mouse tissue 
was stained for human CD3, CD20, cyclin D1 and Ki-67 (Table 5.2). For primary antibodies generated 
in mice (CD20 and Ki-67), a mouse-on-mouse blocking step for an hour, with a M.O.M Mouse Ig 
Blocking Reagent (Vectastain, Burlingame, CA, USA), was introduced prior to primary antibody 
application to prevent binding of secondary anti-mouse immunoglobulin antibody to mouse tissue. 
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Fluorescent in situ hybridisation for IGH: CCND1: Single cell suspensions were prepared from mouse 
spleens that showed MCL infiltration. Spleens were harvested and placed in 10ml ice-cold PBS+2% 
FCS. A 70µm filter (BD biosciences) was placed over a 50 ml falcon tube and spleens were mashed on 
the filter using the end of a plunger from a 1ml syringe. The filter was rinsed through with 
PBS+2%FCS. The effluent was washed once and incubated with 5ml of RBC Lysis Buffer (e-Bioscience, 
San Diego, CA, USA) on a roller at room temperature for 5 minutes after which the reaction was 
quenched with 20mls of PBS. After another wash, cell counts were performed and approximately 107 
cells were transported to the cytogenetics laboratory at the Royal London Hospital for FISH analysis 
as previously detailed.    
 
Table 5.2 Details of primary antibodies and IHC conditions used for staining of tissue harvested from 
NSG mice at sacrifice 
Primary 
antibody  
Supplier  Species  
(clone)  
Antigen  
retrieval  
Concentration  Incubation  
CD3 Labvision Rabbit monoclonal (SP7) Citrate pH6  1:500  40”  
CD20  Dako Mouse monoclonal (L26) Citrate pH6  1:2000  40”  
Cyclin D1  Labvision Rabbit monoclonal (SP4) Citrate pH6  1:50  40”  
Ki-67 Dako Mouse monoclonal (MIB1) Citrate pH6 1:1000 40” 
 
 
 
 
Figure 5.1 Plan of investigation for establishing a NSG model of human primary MCL 
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5.3 DISSEMINATED XENOGRAFT MODEL OF JEKO-1 IN NSG MICE 
 
 
Luciferase-transduced Jeko-1 cells were injected at 2 concentrations (0.5 x 106 and 2 x 106) into a 
total of 6 mice. Mice were identified by ear marks (1, 2 or 3) on the left (L) or right (R) ears. For these 
experiments mice injected with 0.5 x 106 Jeko-1 cells were 1R, 2R and 3R while mice injected with 2 x 
106 cells were 1L1R, 2L and 3L. By day 29, all mice were ill with marked weight loss and had to be 
sacrificed. Some hind leg weakness was noted in mice, particularly in those injected with the higher 
concentration of Jeko-1 cells. Until day 21, mice injected with the lower concentration (0.5 x 106) of 
Jeko-1 cells appeared to have a similar rate of dissemination as mice injected with 2 x 106 cells by 
BLI. In vivo imaging on day 29 showed markedly greater luminescence in mice injected with 2 x 106 
cells. Bioluminescence was observed primarily in the bone marrow, spleen and spinal regions of all 
mice. Representative anterior and posterior luminescence images of mice injected with 2 x 106 cells 
on day 7 are displayed in figure 5.2. D-luciferin diffuses across the blood-brain barrier and 
enhancement of the spinal cord and brain indicates CNS infiltration of Jeko-1 cells which may 
account for hind leg weakness in the mice. Total bioluminescence (average of 3 replicates), reflecting 
the kinetics and disease burden with injection of the two concentrations of Jeko-1 cells are plotted in 
the graphs accompanying figure 5.3.  
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Figure 5.2 Images of bioluminescence in NSG mice on day 7 after injection of Jeko-1 cells. (A) 
Posterior images showing luminescence the pelvis, femurs, spine, cranial and splenic regions of 
mice. (B) Anterior images showing luminescence in the femoral and sternal regions. The regions 
of interest (ROI) for bioluminescent readings are marked in red.   
A. 
B. 
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Figure 5.3 Growth kinetics of Jeko-1 cells in NSG mice estimated by in vivo bioluminescent 
imaging. (A) Graph showing progressive increase in bioluminescence over 4 weeks from 3 mice 
(3R, 2R and 1R) injected with 0.5 x 106 cells. (B) Graph of bioluminescence from 3 mice (3L, 2L, 
1L1R) injected with 2x 106 cells. (C) A comparison of average bioluminescence in the 2 groups of 
mice showing a rapid increase after 21 days in mice injected with a higher concentration of Jeko-1 
cells. 
A. 
B. 
C. 
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5.4 DISSEMINATED XENOGRAFT MODEL OF HUMAN PRIMARY MCL IN NSG MICE 
 
5.4.1 Characterisation of primary samples 
Flow cytometry was performed for immunophenotyping and assessment of T-cell content following 
magnetic T-cell depletion on the three primary MCL samples listed in table 5.1. While all 3 samples 
were positive by FISH for the IGH: CCND1 translocation, primary samples 1 and 3 had dual CD5 and 
CD20 expression and primary sample 2 had weak CD5 expression. This was consistent with lymph 
node histopathology for sample 2 at diagnosis. Samples had less than 10% T-cells and this fell to less 
than 1% with magnetic T-cell depletion. Of the three primary samples injected, only sample 1 was 
seen to engraft consistently. The results in this chapter will therefore focus on this primary sample 
and draw comparisons of this sample with samples 2 and 3 where relevant. Findings in mice injected 
with samples 2 and 3 are detailed in appendix C.  Figure 5.4 shows immunohphenotyping plots and 
further clinical details for primary sample 1. 
 
Figure 5.4 Clinical details and immunophenotypic characteristics of primary sample 1 
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5.4.2 Evidence for engraftment of human primary MCL in NSG mice 
 
T-cell depleted PBMCs from primary sample 1 were injected into a total of 4 mice identified as 1R, 
2R, 3R and NEM (no ear mark). Mice were not visibly ill through the period of monitoring and up 
until sacrifice at 20 weeks. Peripheral blood sampling at 3 weeks revealed less than 1% human CD45 
cells by flow cytometry in all mice. At 6 and 12 weeks a distinct human CD45 population was 
detected in all mice and more than 95% of these cells exhibited dual CD5 and CD20 expression. 
Results of peripheral blood flow cytometry at 12 weeks are shown in figure 5.5A. The growth kinetics 
of injected cells varied between the replicates (figure 5.6B).  
 
 
Mice were sacrificed at 20 weeks and 2-3 cm splenomegaly was noted in all mice at autopsy, while 
spleen from mice that had no evidence of engraftment measured upto 1cm. Some mice had 
hepatomegaly in addition but no obvious lymphadenopathy or intra-abdominal masses were 
detected on exploratory dissection at sacrifice. Flow cytometry performed on flushed bone marrow 
showed a distinct CD5 and CD20 expressing population of tumour cells (Figure 5.6A). CD20 IHC 
performed on femoral and pelvic bone marrow of mice confirmed the presence of MCL cells in a 
scattered pattern (Figure 5.6B). Similar scattered CD20 expressing cells were seen on liver IHC. 
 
Spleens from all mice showed heavily infiltration. Loss of splenic architecture was seen on comparing 
haematoxylin-eosin stained sections between normal spleens from NSG mice (injected with primary 
samples 2 and 3) and infiltrated spleen from mice injected with primary sample 1 (Figure 5.7). CD20 
and cyclin D1 staining of the infiltrated spleens further confirmed engraftment (Figure 5.8). Ki-67 
was performed on the spleens and ranged between 30 and 40% in all spleens. Finally, molecular 
confirmation for engraftment was obtained by performing FISH for the IGH: CCND1 translocation on 
a cell suspension prepared from one of the infiltrated spleens, and this was positive in over 90% of 
cells. No evidence of infiltration was seen in the ileo-caecal junctions of mice. 
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Figure 5.5 Peripheral blood flow cytometry monitoring of MCL engraftment in NSG mice. (A) 
Flow cytometry plots at 12 weeks from 4 NSG mice (1R, 2R, 3R, NEM) injected with primary 
sample 1. Gating of cells positive for human CD45 (hCD45, top row) was followed by detection of 
CD5/CD20 double staining cells (bottom row). (B) Dot plot showing progressive increase in the 
percentage of hCD45 cells in the 4 mice at 3, 6 and 12 weeks. Lines represent mean %hCD45. 
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Figure 5.6 Immunophenotyping of bone marrow cells obtained from NSG mice at sacrifice. (A) 
Flow cytometry analysis showing a distinct human CD5/CD20 double staining population in cells 
flushed out from femurs of mice. (B) Scattered CD20 positive cells seen on IHC staining of 
decalcified, paraffin embedded femoral bone marrow of mice. 
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Figure 5.7 Disruption of splenic architecture by MCL infiltration. A haematoxylin and eosin stained section of spleen harvested from a NSG 
mouse injected with primary sample 2 (left) showing normal splenic architecture compared to the image on the right from a mouse injected 
with primary sample 1. Areas of infiltration are seen as lighter staining regions and are most prominent around vascular structures in the 
spleen.  
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Figure 5.8 Images of CD20 and cyclin D1 IHC on spleen sections from NSG mice showing MCL infiltration. FFPE sections of spleens from 4 mice (1R, 2R, 
3R and NEM) showing heavy infiltration with CD20 (top row) and cyclin D1 expressing cells. The inset in IHC images for 1R show CD20 and cyclin D1 
staining at a higher magnification. 
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5.4.3 Secondary transplantation 
Single cells suspensions prepared from spleens of NSG mice that showed engraftment with primary 
sample 1 were cryopreserved in 90% FCS and 10% DMSO. Cells were thawed in a water bath and re-
suspended in RPMI+10% FCS for performing cell counts. For secondary transplantation, 3 x 107 cells 
were re-suspended in 600μl of PBS + 10%FCS and injected by tail-vein into 3 NSG mice (1R, 2R and 
NEM) that were irradiated within 24 hours of cell injection. Peripheral blood flow cytometry 
performed at 6 and 12 weeks showed a distinct CD5/CD20 double positive population (Figure 5.9A). 
Once again, mice showed no signs of illness until sacrifice. At 20 week sacrifice, 2 out of 3 mice (2R 
and NEM) had marked splenomegaly. No other obvious masses were found at autopsy. IHC for CD20 
and cyclin D1 confirmed heavy infiltration of the spleen in all 3 mice. Flow cytometry of cells flushed 
out from the bone marrow showed a small population of CD5/CD20 double positive cells that was 
most obvious in 2R, less so in NEM and not detected in 1R. These differences are very likely due to a 
smaller cell dose injected into mouse 1R as it was the last mouse injected. 
 
 
 
 
Figure 5.9 Engraftment of MCL cells with secondary transplantation of primary sample 1 at 20 
weeks (A) CD5/CD20 double positive cells in peripheral blood. (B) and (C) CD20 positive cells in 
the bone marrow and spleen of mice. (D) Infiltration of spleen with cyclin D1 expressing cells. 
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5.5 Discussion 
 
This preliminary study demonstrates that human primary mantle cell lymphoma can be established 
in NSG mice. Disseminated models of MCL cell lines in immunodeficient mice have been previously 
used for pre-clinical testing of drugs. We used a disseminated model of Jeko-1 to predict kinetics and 
distribution with primary cells. This provided some insights – firstly, the cell dose injected appears to 
correlate with the kinetics and burden of engraftment and secondly the bone marrow and spleen 
were common sites of involvement. The aggressiveness of the Jeko-1 cell line in the NSG model is 
also of note with rapid dissemination in mice resulting in illness at 4-5 weeks. 
 
We saw engraftment of only one of the three primary samples injected into the NSG mice. Although 
this is a limited number of samples, the sample that engrafted was from a patient with relapsed, 
blastoid disease suggesting that an aggressive phenotype is more likely to favour engraftment in this 
model. This is in keeping with observations from other NSG models of human malignancy such as 
acute myeloid leukaemia.180 Engraftment of MCL was confirmed by immunophenotyping and FISH 
for IGH: CCND1. We saw MCL involvement of spleen, bone marrow and peripheral blood in the mice, 
similar to that seen in the patient from whom these cells were harvested. No tumour masses or 
lymphadenopathy was detected and the ileo-caecal junction showed no evidence of infiltration in 
these mice. Indeed, it is not known if lymphadenopathy can be expected in these mice that lack both 
B-cells and T-cells. Interestingly, mice were not visibly ill at 20 weeks despite widespread infiltration 
but this is likely to occur with longer observation. This may however be an advantage for pre-clinical 
testing as drugs can be administered for adequate periods of time in order to test their effect on 
reduction of disease burden compared to untreated controls.  
 
The failure of engraftment of the two other samples also needs to be discussed. One option may be 
to increase the cell dose administered to mice but this is not as easy as with CLL where patient 
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samples are more readily available. The same argument holds for evaluating freshly isolated cells 
from patients compared to cryopreserved cells that were used in our study. A third option is to 
evaluate the effect of co-transplanting tumour cells with allogeneic T-cells as described in the NSG 
model of human primary CLL. While there is evidence for a protective role for T-cells in CLL, evidence 
for this in MCL is scant. We used a conservative strategy of depleting T-cells prior to injection of mice 
because an expansion of T-cells has often seen by our collaborators after injection of PBMCs into 
NSG mice and these often ‘out-compete’ tumour cells.  
 
Finally, we were able to establish MCL in a new set of NSG mice by secondary transplantation of cells 
derived from spleens of mice that had engrafted. This supports the self-renewal and tumour-
initiating capacity of MCL cells. While this NSG model needs further refining to improve the rate of 
engraftment, it is a promising in vivo model for both pre-clinical drug testing and for improving our 
understanding of MCL biology for e.g. through studies of tumour initiating cells or co-transplantation 
of allogeneic T-cells. A good understanding of the benefits and limitations of this model is necessary 
in order to interpret findings and use it effectively. 
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CHAPTER 6: FINAL DISCUSSION AND FURTHER WORK 
 
6.1 Discussion and translational relevance 
 
In vitro studies have demonstrated an important role for the PI3K pathway in MCL pathogenesis. The 
p110δ isoform of PI3K is highly enriched in leucocytes and is therefore an attractive target in 
lymphomas. However, relatively inferior responses to the p110δ inhibitor GS-1101 were reported in 
relapsed/ refractory MCL compared to indolent NHL. This may imply a role for other isoforms in the 
survival of MCL cells or may simply mean that this pathway is not as important as in vitro studies 
suggest. The hypothesis for this research was based on the former theory i.e. the contribution of 
other class Ia isoforms, particularly p110α, may explain the relatively inferior responses to GS-1101. 
This hypothesis was supported by evidence from a previous study that demonstrated PIK3CA 
amplification in approximately two-thirds of MCL cases (68%).144 However, the relative expression of 
class Ia isoforms and the implications of PIK3CA amplification for MCL survival were not evaluated in 
this study. We therefore elected to evaluate the expression of class Ia isoforms in MCL and study 
their relative importance in the setting of PIK3CA amplification, B-cell receptor engagement, IL4 
stimulation and loss of PTEN expression 
 
Of the three class Ia isoforms (p110α, p110β and p110δ), immunohistochemistry for p110δ on 
human tissues had not been described at the time of starting these studies and therefore initial work 
focussed on validation and optimisation of an antibody against p110δ that could be used in human 
FFPE tissue. In parallel, MCL biopsies stored over a period of 36 years from patients treated at Barts 
hospital were incorporated into a TMA to study the expression of the important tumour suppressor 
phosphatase PTEN and the class Ia isoforms. Tonsils excised for non-malignant pathology were 
incorporated into the TMAs as benign controls.  
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There were some limitations to using this collection of MCL biopsies. Firstly, there was a relatively 
high number of poor quality cores and therefore loss of cores on the TMAs with repeated sections 
and secondly, the number of diagnostic samples was relatively small owing to the tertiary referral 
centre care provided at St. Bartholomew’s hospital thereby limiting the ability to perform 
meaningful survival studies. On the other hand, this represents one of the largest MCL cohorts 
studied with respect to the PI3K pathway and provided the opportunity to study changes with 
disease progression in this rare lymphoma. 
 
Studies in MCL have suggested an important role for suppression or inactivation of PTEN in MCL. In 
keeping with previous observations,22,144 loss of PTEN expression was found in 17% of diagnostic and 
16% of all biopsies. As there is evidence that p110β plays an important role in solid tumour cells 
exhibiting loss of PTEN expression,145 the addition of a p110β inhibitor (TGX221) to GS1101 was 
evaluated in 2 primary samples exhibiting loss of PTEN expression. Although no increased 
cytotoxicity was found with addition of TGX221, it is difficult to draw firm conclusions from this 
limited number, particularly as other mechanisms of PTEN inactivation such as phosphorylation and 
microRNA induced suppression were not investigated. However, these studies confirm that loss of 
PTEN expression is a relatively common phenomenon in MCL. They also demonstrate a non 
significant increase of PTEN expression loss with blastoid transformation (15% of classical MCL vs. 
20% blastoid MCL) and no significant change in isoform expression in these cases compared to MCL 
with intact PTEN expression. The implications of this molecular aberration in MCL are however not 
entirely clear and need further study.   
 
Overall, the expression of the class Ia isoforms in MCL followed that seen in tonsil controls with 
p110δ showing the strongest expression. However, two differences between tonsils and MCL were 
observed – firstly, the expression of p110β in MCL was significantly lower than expression in tonsil 
controls and secondly, p110α expression showed wide variation within MCL samples. The first 
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important and interesting finding on correlating these findings to clinical information was that p110α 
was significantly higher in biopsies taken beyond 1st relapse compared to those taken at diagnosis 
while the expression of p110β and p110δ was not significantly different between diagnosis and 
relapse. The importance of increased p110α expression was studied in the Granta519 MCL cell line 
which exhibits constitutive Akt phosphorylation and increased p110α expression. Use of isoform 
selective inhibitors in this cell line revealed that p110δ inhibition with GS-1101 was insufficient for 
effective PI3K inhibition but addition of a p110α inhibitor (but not a p110β inhibitor) to GS-1101 
resulted in complete PI3K inhibition. Further studies carried out with GDC-0941, a dual p110α and δ 
inhibitor showed that dual inhibition was necessary for not just complete but also sustained PI3K 
inhibition in the setting of increased p110α expression. Further, GDC-0941 treatment was found to 
have significantly greater activity in MCL cell lines and primary samples compared to GS-1101.  
 
In relation to external stimuli, however, it appeared that p110δ inhibition was sufficient to abolish 
BCR induced PI3K activation and did not differ significantly from GDC-0941 in its ability to counteract 
the proliferative effects of IL4 in primary MCL cells. These findings suggest that while p110δ is 
important for PI3K activation mediated by external stimuli, p110α appears to primarily support 
constitutive PI3K activation in MCL. MCL cells exhibiting PIK3CA/p110α over-expression can 
therefore sustain PI3K signalling despite p110δ inhibition. These findings are unlikely to be 
influenced by p110γ as both GS-1101 and GDC-0941 have very similar activity against this isoform. 
 
Two studies particularly relevant to these findings merit mention at this stage. The first by Ramadani 
et al provides evidence that although p110δ is the key isoform in relation to agonist-induced BCR 
signalling, p110α contributes to tonic BCR signalling in healthy lymphocytes.169 So while p110δ 
appears to retain its role in MCL, increased expression of p110α, may confer a benefit through 
increased p110α-induced tonic signalling. The second study by Hui et al demonstrates a role for 
increased expression of PIK3CA in chemo-resistance.130 Chronic exposure of K562 cells to 
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doxorubicin was found to induce nuclear accumulation of FOXO3a which in turn led to increased 
expression of PIK3CA (and p110α) through FOXO3a induced activation of the PIK3CA promoter 
region. Activation of the PI3K pathway through PIK3CA amplification conferred resistance to 
doxorubicin in these cells. This mechanism of PIK3CA/p110α amplification may explain the reason 
why increase in p110α is most significant with increasing chemotherapy exposure i.e. beyond 1st 
relapse in MCL. However, another possible mechanism is the selection and expansion of a pre-
existing clone of high PIK3CA/p110α expressing cells by repeated cycles of chemotherapy that 
eliminates chemo-sensitive cells. Support for the latter mechanism can perhaps be found in the 
results of data mining of class Ia PI3K gene expression that demonstrated a significantly higher 
PIK3CA in MCL compared to indolent NHL even at diagnosis. Immunohistochemistry does not allow 
differentiation of these mechanisms and indeed, both mechanisms may co-exist. It is interesting that 
an increase in PIK3CA was not found in sequential follicular lymphoma biopsies and this may once 
again suggest a pre-existing clone of high PIK3CA expressing cells in MCL that selectively expands in 
response to chemotherapy. A further IHC study looking at the expression of nuclear FOXO3a with 
MCL progression as well as a study of p110α expression in diagnostic biopsies and its impact on 
survival can provide further insight into this process. A summary of the proposed mechanisms by 
which increased p110α may confer a survival advantage in MCL cells is depicted in figure 6.1. 
 
The evaluation of phosphorylation of downstream targets of PI3K yielded inconsistent results. 
Neither the degree of Akt phosphorylation nor inhibition of phosphorylation in response to PI3K 
inhibition appeared to predict sensitivity. One interpretation could be that constitutive PI3K 
activation is not always associated with Akt phosphorylation and a more reliable marker is needed. 
This view is supported by observations that constitutive Akt phosphorylation is not always seen in 
cells harbouring activating mutations in PIK3CA.181 However, Akt phosphorylation when detected is a 
useful marker to detect the degree of PI3K inhibition. Phosphorylation of ribosomal S6 may be a 
useful marker in the absence of detectable Akt phosphorylation. Another aspect of these studies 
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Figure 6.1 Proposed role of p110α in MCL 
pathogenesis (A) P110δ is the key isoform in 
agonist induced BCR signalling in healthy cells 
and MCL. (B) P110α contributes to tonic agonist-
independent signalling as proposed by Ramadani 
et al. (C) Increased expression of p110α with 
relapse can be as a result of expansion of a high 
expressing clone or chemotherapy induced 
increase in p110α. (D) Increased contribution to 
tonic/constitutive PI3K signalling in MCL cells that 
exhibit increased p110α expression and/or a high 
PIK3CA/PIK3CD ratio. P110δ inhibition is likely to 
have a limited effect in these cells. 
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was the lack of association between successful PI3K inhibition with pharmacological inhibitors, as 
judged by inhibition of Akt phosphorylation, and their effect on growth inhibition or cytotoxicity. It is 
very likely that a subset of MCLs either do not rely on the PI3K pathway for survival or are able to 
activate alternate survival pathways in response to PI3K inhibition. A recent study in T-ALL suggests 
an important role for activation of the NOTCH pathway as a mechanism of resistance to PI3K/mTOR 
inhibition.176 This may be a particularly interesting pathway for study in relation to resistance to PI3K 
inhibition in MCL as NOTCH mutations are found in approximately 12% of MCL cases and this 
pathway is therefore likely to play an important role in at least a subset of MCL.  
 
In order to determine the potential implications of increased PIK3CA in MCL, we studied the gene 
expression of the class Ia isoforms using qRT-PCR. The ΔCt method was used for relative quantitation 
of gene expression and B-cells from healthy PBMCs were used as controls. Although a higher PIK3CA 
expression by itself was not predictive of resistance to GS-1101, the PIK3CA/PIK3CD mRNA ratio was 
found to be predictive of resistance to GS-1101 in vitro in an initial cohort of 12 primary MCL 
samples. Resistant samples were found to have a ratio that was greater than twice the ratio found in 
healthy B-cells. This cut-off was validated in an independent cohort of 10 samples. As this marker of 
resistance employs an internal healthy control to determine the cut-off, it is less likely to suffer from 
variability and is therefore more likely to be reproducible. It also reflects the mechanism proposed 
for resistance of MCL cells to p110δ inhibition i.e. high relative expression of PIK3CA. The recent 
synthesis and availability of the selective p110α inhibitor A66164 allowed us to evaluate the effect of 
p110α inhibition on its own in MCL. This inhibitor had no significant cytotoxicity in Jeko-1, Granta 
519 and 10 primary MCL samples that were studied. This further supports the role for dual p110α/δ 
inhibition in MCL. 
 
One of the limitations of the cytotoxicity studies was the lack of availability of sequential PBMCs 
from MCL patients. However, sequential frozen MCL lymph nodes were available and gene 
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expression of class Ia isoforms was therefore determined on these using qRT-PCR.  In keeping with 
the IHC studies, the PIK3CA/PIK3CD ratio was higher at relapse compared to diagnosis in these 
sequential biopsies. Of note, gene expression of class Ia PI3K isoforms in frozen MCL was observed 
to differ from that seen in MCL PBMCs in that the expression of p110α appeared to be lower in 
relation to p110δ in frozen nodes compare to PBMCs. Gene expression on purified MCL cells from 
lymph node and peripheral blood samples taken simultaneously from a patient are required to 
confirm this finding but potential explanations are a higher proportion of non-tumour cells in lymph 
nodes compared to PBMCs and perhaps a reversible down-regulation of PIK3CA expression induced 
by the lymph node micro-environment. 
 
Our observation that the PIK3CA/PIK3CD mRNA ratio increases with relapse as does p110α 
expression implies that these inhibitors may be particularly useful in relapsed MCL. However, as 
increased PIK3CA/p110α expression appears to be associated with relapse, and potentially chemo-
resistance, it could be argued that there is a rationale for using dual p110α/δ inhibition either 
upfront or as maintenance therapy in patients who attain remission.  On the other hand, as MCL is 
as yet an incurable disease, the PIK3CA/PIK3CD ratio may be useful to determine which patients 
would benefit most from dual inhibition. Those with a low PIK3CA/PIK3CD ratio may benefit equally 
from a p110δ inhibitor such as GS-1101 while dual inhibition could be reserved for relapsed disease 
or when a high PIK3CA/PIK3CD ratio becomes apparent.  
 
The results obtained from data mining of class Ia PI3K isoform gene expression taken together with 
the finding that p110α expression appears not to change with disease progression in follicular 
lymphoma suggest that targeting p110α is particularly important in MCL. It is possible that the 
genetic instability seen with MCL, which is not as prominent with indolent NHL, lends itself to this 
phenomenon and it would be interesting to study changes in p110α with progression in aggressive 
lymphomas.     
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Although initially intended to provide in vivo validation for the results discussed above, the final 
aspect of this research moved away from this idea and towards the exciting possibility of 
establishing human MCL in NSG mice. From the perspective of a rapidly expanding armamentarium 
of potential therapies, a mouse model for pre-clinical drug testing is particularly valuable for a rare 
disease like MCL. Three MCL samples from three individual patients were injected into NSG mice in 
order to evaluate their ability to engraft in this model. Engraftment was seen in only one of the 3 
samples injected but was seen consistently across all 4 replicate mice. This sample was from a 
patient with relapsed, blastoid disease suggesting that an aggressive phenotype may favour 
engraftment. Similar observations of favourable engraftment in cells from patients with a worse 
outcome have been reported in NSG models of human AML.180 In addition, we found engraftment 
following serial transplantation of the spleen cells from affected mice. This supports the self-renewal 
and tumour initiation capacity of these MCL cells. Engraftment in mice was confirmed with both 
immunophenotyping (human CD20 and cyclin D1) and FISH analysis for t(11;14) in cells from NSG 
spleen. 
 
While this data is preliminary, it demonstrates that it is possible to establish human primary MCL in 
NSG mice. This model can be used for pre-clinical testing of drugs as well as for studying certain 
aspects of MCL biology such as tumour-initiating cells. The obvious limitation of this model is the 
lack of micro-environment (B-cells, T-cells and NK cells). It is therefore important to develop this 
model keeping in mind its advantages and limitations. There may be ways to improve engraftment 
that need further exploration and these include using a higher cell dose, using a different cell source 
(for e.g. spleen, bone marrow) and using alternative conditioning of mice. 
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6.2 Further work 
 
While further studies are required to establish the role of p110α in chemo-resistance and disease 
progression, these studies should not delay the evaluation of dual p110α/δ inhibition in a clinical 
trial with MCL patients, particularly as dual p110α/δ inhibitors like GDC-0941 have been relatively 
well tolerated in early phase clinical trials in solid tumours. The expression of p110α needs to be 
investigated in a large cohort of diagnostic MCL samples in relation to progression free and overall 
survival. Functional studies in MCL cell lines of the relationship between FOXO3a, PIK3CA and 
chemo-resistance in conjunction with an immunohistochemistry study of the localisation of FOXO3a 
in MCL cells in relation to p110α expression and disease progression may help to elucidate the 
mechanism behind the higher expression of this PI3K isoform in relapsed disease.  Simultaneous 
studies in follicular lymphoma, which does not appear to exhibit an increase in p110α with relapse, 
would also be useful to investigate whether increased p110α expression with disease progression is 
in fact related to chemotherapy induced nuclear accumulation of FOXO3a.  
 
Evaluation of the PIK3CA/PIK3CD ratio in MCL cells from GS-1101 treated patients and correlation 
with clinical response would provide a robust test of this ratio as a biomarker. A clinical trial with a 
dual p110α/δ inhibitor such as GDC-0941 could take the form of a phase II study in 
relapsed/refractory MCL patients where patients receive a cycle of the p110α/δ inhibitor prior to a 
salvage chemotherapy regimen followed by the option of maintenance with a p110α/δ inhibitor if a 
response is achieved. PIK3CA/PIK3CD ratio on tumour cells (blood, bone marrow or lymph node) 
prior to starting treatment can then be correlated with response to treatment.  
 
Although important, PI3K inhibition is not always effective against MCL cells and other survival 
pathways may be able to sustain survival in the absence of PI3K signalling. In relation to 
haematological malignancy, targets that may be important in view of recent evidence are CDK4/6, 
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mTOR and NOTCH signalling pathways. Combining an mTOR inhibitor (Everolimus or Temsirolimus) 
or CDK4/6 inhibitor with GS-1101 has been shown to have a greater effect than GS-1101 alone171,172 
while a separate study describes promising activity with PI3K/mTOR inhibitors in MCL cells in vitro. 
182Another particularly attractive pathway to investigate is the NOTCH signalling pathway as its 
activation has been shown to impair responses to PI3K/mTOR inhibition in T-ALL176 and 
approximately 12% of all MCL cases are found to carry NOTCH mutations.27 As previously discussed, 
targeting a greater number of pathways is likely to lead to greater toxicity but the simultaneous 
evaluation of predictive markers may aid appropriate selection of patients.  
 
In relation to the NSG model of human primary MCL, further work is required to investigate 
conditions that may favour engraftment of patient derived MCL cells. These could include changing 
cell conditions such as injecting a higher cell number, comparing fresh cells to cryopreserved cells, 
using a different cell source and injecting whole PBMCs instead of T-cell depleted PBMCs. Mouse 
conditions such as using more humanised mice or using alternative conditioning of mice could also 
be explored.  The obvious limitation to using this model is the lack of immune cells (T-cells, B-cells 
and NK cells) and therefore lack of a representative tumour microenvironment. On the other hand, 
this is still a useful model to study the direct tumour toxicity of molecular therapies and is also 
potentially useful to study the role of other components of the tumour microenvironment such as 
angiogenesis and macrophages. Other potential uses for this model include the exploration and 
isolation of MCL-initiating cells by serial transplantation of lymphoma sub-populations. Further 
studies in the NSG mice that are on-going include injection of additional primary MCL cells from 
different sources (peripheral blood, lymph node, bone marrow or spleen), comparing engraftment 
between T-cell depleted and whole PBMCs from the same patient and evaluation of characteristics 
that may predict which samples will engraft in NSG mice. 
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In conclusion, despite advances in therapy, MCL remains an incurable disease characterised by 
frequent relapse. This research provides evidence for the potential role of p110α in disease 
progression and resistance to p110δ inhibitors in MCL. Further work should focus on investigating 
the role of p110α in MCL chemo-resistance and also evaluating dual p110α/δ inhibitors in the clinical 
setting with the incorporation of the PIK3CA/PIK3CD ratio as a biomarker. Finally, it is likely that a 
rational combination of molecular therapies will be required for optimal control or perhaps even 
cure in MCL but the rarity of this disease makes this challenging. We provide preliminary data for a 
mouse model of human MCL that can be used for pre-clinical testing of novel molecular therapies 
and their combinations. This model needs to be refined but is a potentially valuable tool for pre-
clinical testing of novel therapies and also one that could advance our understanding of MCL biology 
and thereby take us a step further towards overcoming this rare but as yet incurable lymphoma. 
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APPENDIX 
 
APPENDIX A 
 
Preparing cell blocks from cell suspensions 
 
Two methods of cell block preparation, one using agar and the other using thrombin, were 
compared. The thrombin cell block method was superior at preserving cell morphology and was less 
time consuming.  A comparison of the morphology obtained by using the two methods with the 
K562 cell line is shown in figure A1. 
 
Agar cell block: 2% agar was prepared by adding 1g of powdered agar to 50ml PBS in a beaker. The 
solution was heated in a microwave at low power until all the agar had dissolved and a clear solution 
was obtained (approximately 2 minutes). The beaker was then placed in a pre-heated water bath at 
50ᵒC. Approximately 10-15 x 106 cells were centrifuged at 400xg for 5 minutes in a 15ml conical 
tube. The tube was inverted on filter paper for a minute and placed in the same water bath as the 
beaker for 1-2 minutes. The agar solution was then added in equal volume to the cells and the 
mixture was agitated. Following centrifugation at 100xg for 2 minutes, the agar was allowed to set 
by incubating the tube for 10-15 minutes at 4ᵒC. The block was then gently teased out into formalin 
for fixation and subsequent embedding in paraffin. 
 
Thrombin cell block: Approximately 10-15 x 106 cells were centrifuged at 400xg for 5 minutes in a 
15ml conical tube. The tube was then inverted over filter paper for one minute following which the 
pellet was re-suspended in 3 to 5 drops each of human control plasma and thromboplastin. Once 
congealed into a fibrin clot, the block was left at 4°C for 15 minutes. This was then gently teased out 
into formalin for fixation and subsequent embedding in paraffin. 
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Figure A1 Comparative morphology of agar and thrombin cell blocks prepared from the K562 
leukaemia cell line 
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APPENDIX B 
 
 
A summary of clinical information and IHC scores for samples in the MCL TMA 
 
 
As described in chapter 2, the large majority of MCL biopsies incorporated into the TMA were taken 
from patients with relapsed lymphoma. The cores were divided among 6 TMA slides 03A-2009 to 
03F-2009.  TMA slide maps were constructed with rows on the grid labelled alphabetically and 
columns labelled numerically. Each core could therefore be identified by the TMA slide number (e.g. 
TMA-03A-2009) and row/column co-ordinates (e.g. B12). Triplicate cores were arrayed 
consecutively, for e.g. A01-A03.  The table on the following page (Table A1) displays average scores 
against the 1st core of the triplicate e.g. A01. Scores for the class Ia isoforms p110alpha, p110beta 
and p110delta were derived from visual analysis parameters obtained from Ariol SL-50 version 3.2 
while PTEN and Ki67 were scored by eye (Dr Abigail Lee and Dr Sunil Iyengar).   
 
Clinical information relating to timing of the biopsy and overall survival were kindly provided by 
Janet Mathews and Dr Rebecca Auer. Information on blastoid morphology was obtained from the 
original biopsy reports and confirmed on the TMA slides by Dr Maria Calaminici.   
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Table A1. Summary of IHC scores for class Ia PI3K isoforms, PTEN and Ki-67 and clinical information relating to MCL cores studied using the TMA technique (OS=overall 
survival). 
 
TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03A-2009 A01 6358898 Relapse  
 
55.72 82.86 70.39 1 93.7 yes 
03A-2009 A04 F719526 1st relapse 
 
39.11 5.51 76.86 1 23 
 03A-2009 B03 M609903 Diagnosis/pretreatment 30 39.43 0.28 102.45 1 13 
 03A-2009 B09 M508414 Relapse  
 
22.45 7.28 78.21 neg 2.3 
 03A-2009 B12 M658480 Relapse  
 
16.4 0.92 81.20 1 20 
 03A-2009 C01 6307612 Relapse  
 
30.91 8.77 91.86 2 73.3 yes 
03E-2009 F09 6517867 4th Relapse 
 
44.36 0.72 82.72 1 21.7 
 03E-2009 F12 6517867 4th Relapse 
 
58.43 1.79 87.00 2 21.7 
 03A-2009 C05 6043657 1st relapse  
 
28.35 1.09 61.42 1 22.3 
 03A-2009 C08 M87891 Diagnosis/pretreatment 65 
   
neg 
  03A-2009 C11 M87891 2nd relapse 
 
5.78 0.44 44.45 neg 2 
 03A-2009 D01 M502305 Relapse  
 
60.06 19.73 68.34 1 21.3 
 03A-2009 D04 M502305 Relapse  
 
96.03 9.04 86.58 
 
15.5 
 03A-2009 D07 F616651 Diagnosis/pretreatment 25 6.87 15.17 66.57 1 
  03A-2009 D10 M287253 Diagnosis/pretreatment 24 97.8 68.65 72.50 2 6.7 
 03A-2009 D13 F624798 Diagnosis/pretreatment 60 53.23 26.32 95.81 1 17 
 03A-2009 E03 F624798 1st relapse 
 
95.68 
 
87.70 1 3 
 03A-2009 E06 F624798 2nd relapse 
 
119.11 71.48 80.13 1 18.3 
 03A-2009 E09 M631054 Diagnosis/pretreatment 
 
46.6 20.8 92.07 
 
51.7 yes 
03A-2009 E12 M580030 Diagnosis/pretreatment 33 9.51 1.96 97.63 1 5 
 03A-2009 F01 M580030 1st relapse 
 
19.7 0.29 97.39 1 19 
 03A-2009 F04 M580030 2nd relapse 
 
84.3 4 79.38 1 22.7 
 03E-2009 C06 6260113 Relapse  
 
23.28 
 
38.33 
 
26 
 03E-2009 C09 6260113 1st relapse 
 
19.35 0.13 42.01 1 16 
 03A-2009 F07 M581475 Diagnosis/pretreatment 58 21.69 1.15 82.57 1 3.3 
 03A-2009 F10 M581475 3rd relapse 
 
94.47 2.7 83.13 1 6.7 
 03F-2009 B04 6174385 1st relapse 
 
58.17 4.31 97.54 
 
39 
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TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03A-2009 F13 M684797  3rd Relapse 
 
106.92 3.32 88.19 1 49.3 
 03A-2009 G05 M768355  Not known 
 
69.99 9.9 73.44 1 24 
 03A-2009 G09 6176589 1st relapse 
 
34.99 4.21 64.88 2 21.3 
 03A-2009 G12 M600816 Diagnosis/pretreatment 5 29.48 2.51 13.72 
 
17.7 
 03A-2009 H01 PP Not known  
 
15.33 85.34 48.75 
 
2.3 
 03A-2009 H08 M640685 1st relapse 
 
61.89 117.24 120.34 2 23.3 
 03A-2009 H04 6107842 Diagnosis 
 
90.07 40.2 85.82 1 16.7 
 03F-2009 A11 6107842 Progression 
 
58.63 1.32 96.16 
 
14.7 
 03A-2009 H11 6168205 Relapse  
 
108.98 6.19 102.86 1 20 yes 
03F-2009 B01 6168205 Relapse  
 
77.49 0.14 81.52 1 41 yes 
03A-2009 H14 F584365 Relapse  
 
1.15 0.21 2.76 1 18.7 
 03A-2009 I03 M526896 Relapse  
 
84.55 3.12 94.34 1 10 
 03A-2009 I06 M526896 Relapse  
 
98.34 8.16 77.66 neg 6.7 
 03B-2009 H07 M697593 Diagnosis/pretreatment 20 68.7 27.5 80.22 neg 18.3 yes 
03E-2009 D01 6182106 Relapse  
 
9.71 1.03 20.46 1 37.7 
 03F-2009 B11 6358889 1st relapse blastoid  
 
31.91 11.91 73.75 2 78.3 yes 
03B-2009 A01 M697679 Diagnosis/pretreatment 27 
  
11.30 2 
  03B-2009 A11 M585844 1st relapse  
 
74.1 32.6 87.77 1 11.5 
 03B-2009 A14 M681984 Relapse  
 
109.2 2.64 78.56 
 
3.7 
 03B-2009 B02 M681984 Relapse  
 
  
95.69 1 18 
 03B-2009 B05 6347968 Relapse  
 
59.87 64.76 78.32 2 60.7 yes 
03B-2009 B08 6281796 Diagnosis/pretreatment 28 42.87 6.12 80.52 neg 14 
 03B-2009 B12 F840839 Not known  
 
68.03 23.69 86.31 
 
20.3 
 03B-2009 B15 M594944 Diagnosis/pretreatment 8 33.52 
  
1 
  03B-2009 C03 M779624 Relapse  
 
89.89 10.25 87.78 2 50.7 yes 
03F-2009 A04 M650978 2nd relapse 
 
79.76 4.59 97.05 1 18 
 03B-2009 C12 M614054 Relapse  
 
   
1 
  03E-2009 A05 M783398 Relapsed / refractory 
 
 
2.7 10.04 1 6 
 03B-2009 C15 6227465 Diagnosis/pretreatment 108* 43.06 1.08 82.31 neg 21 
 03E-2009 F02 6227465 2nd relapse 
 
38.6 22.15 91.02 2 17 
 03B-2009 D03 M563251 Relapse  
 
   
1 21 
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TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03B-2009 D07 M563251 Relapse  
 
  
90.54 neg 7 
 03B-2009 D10 M648098 Relapse  
 
130.29 32.07 96.79 
 
14.3 
 03B-2009 D13 PP Not known  
 
103.7 49.05 76.20 1 21.3 
 03E-2009 E11 6390360 Diagnosis/pretreatment 13 35.98 18.77 57.72 
 
97.3 
 03B-2009 E01 245367LC Diagnosis/pretreatment 17 59.85 1.8 55.03 
 
23 
 03B-2009 E04 F523754 Diagnosis/pretreatment 61 
   
1 15.5 
 03B-2009 E07 F523754 3rd relapse 
 
  
94.73 2 24.7 
 03B-2009 E10 F648335 Diagnosis/pretreatment 
 
33.99 12.91 107.93 1 15.5 
 03B-2009 E13 M671739 Diagnosis/pretreatment 111 17.49 2.27 87.63 1 8 
 03B-2009 F02 M671739 1st relapse 
 
79.47 15.09 83.54 1 17.7 
 03B-2009 F08 M671739 2nd relapse 
 
128.96 3.32 88.54 1 18 
 03B-2009 F14 M737477 Diagnosis/pretreatment 24 82.12 34.03 70.78 
 
26.7 
 03B-2009 G02 M737477 1st relapse 
 
70.39 50.58 76.73 
 
26.3 
 03B-2009 G05 M685216 Diagnosis/pretreatment 3 32.06 1.79 45.89 2 13.7 
 03B-2009 G12 M718014 Diagnosis/pretreatment  44 69.84 60.86 79.19 
 
12 
 03E-2009 A08 M579242 Diagnosis/pretreatment nine 
 
3.66 75.95 1 22 
 03B-2009 H03 M599142 Diagnosis/pretreatment 6 
   
1 20.7 
 03B-2009 H10 M768402 Relapse  
 
161.94 1.28 69.00 1 10.3 
 03B-2009 H13 M768402 Relapse  
 
113.89 3.58 76.21 1 15.3 
 03B-2009 I01 M768402 Relapse  
 
135.97 1.88 85.19 1 16.3 
 03F-2009 C01 6437550 Diagnosis/pretreatment  9 37.91 6.78 58.41 2 70.3 yes 
03E-2009 B12 6127836 Diagnosis/pre-treatment 
 
9.37 1.39 72.78 1 17.3 
 03C-2009 A01 6000212 Relapse  
 
37.3 67.61 80.27 2 42.7 
 03E-2009 C03 6026752 1st relapse 
 
14.02 
 
50.05 
 
1 
 03C-2009 A11 M597347 Diagnosis/pretreatment 40 4.99 0.11 30.39 2 23.7 
 03C-2009 A14 M597347 post-treatment 
 
4.78 0.77 65.00 1 13 
 03C-2009 B02 M597347 2nd relapse  
 
88.5 26.5 110.57 1 26 yes 
03C-2009 B06 M604432 Diagnosis/pretreatment 41 24.45 7.26 104.59 1 22.7 yes 
03C-2009 B09 M604432 1st relapse 
 
2.26 7.36 66.10 2 13.7 yes 
03C-2009 B12 M685565 Diagnosis/pretreatment 25 22.81 1.75 35.79 neg 14 yes 
03C-2009 B15 M685565 Diagnosis/pretreatment 
 
29.35 2.95 99.61 
 
18 yes 
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TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03C-2009 C03 M685565 1st relapse - high grade 
 
13.74 3.34 79.33 1 55 yes 
03E-2009 F05 1216497WH 2nd Relapse  
 
58.23 1.66 93.59 2 22 
 03E-2009 G10 1216497WH 2nd relapse (later time point) 
 
35.99 0.3 81.02 2 28 
 03C-2009 C06 M532967 Relapse  
 
44.67 7.94 74.37 1 15.7 
 03C-2009 C09 M532967 Relapse  
 
4.05 0.6 61.14 1 1 
 03C-2009 C12 M756673 Diagnosis/pretreatment 44 27.8 1.58 12.87 1 1 
 03C-2009 C15 M756673 1st relapse 
 
60 25.61 63.42 2 53 yes 
03C-2009 D04 104388HA Relapse  
 
53.59 2.61 92.52 1 17.3 yes 
03C-2009 D07 104388HA Relapse  
 
4.46 
 
94.87 2 33 yes 
03C-2009 D10 F822553 Diagnosis/pretreatment 16 68.62 6.19 98.77 1 17.3 
 03C-2009 D13 M504990 Diagnosis/pretreatment 
 
      03C-2009 E01 M504990 Relapse  
 
21.09 2.02 78.82 neg 30.5 yes 
03C-2009 E04 M504990 Relapse  
 
10.92 3.79 43.06 neg 28.7 yes 
03C-2009 E07 6319093 Relapse  
 
34.92 13.02 82.15 2 80.3 yes 
03C-2009 E13 6182142 Relapse  
 
57.7 1.17 89.28 1 9.3 yes 
03C-2009 F01 M503906 Diagnosis/pretreatment 13 16.48 2.87 84.56 
 
38.5 
 03C-2009 F05 M790203 Diagnosis/pretreatment 
 
53.7 10.23 100.58 1 8.7 
 03C-2009 F08 M715889 Diagnosis/pretreatment 
 
48.96 0.97 96.87 neg 20.3 
 03C-2009 F11 M715889 Relapse  
 
135.56 8.63 96.32 neg 4.3 
 03C-2009 F14 6307615 Not known  
 
30.61 3.06 76.03 2 20 
 03C-2009 G02 M500046 Relapse  
 
58.5 5.48 91.25 1 6.7 
 03C-2009 G06 6023295 Relapse  
 
48.35 0.5 101.07 1 14.3 
 03C-2009 G09 M507789 Diagnosis/pretreatment 21 49.99 6.83 70.49 1 17.7 
 03C-2009 G12 M507789 1st relapse 
 
18.52 1.43 98.19 1 19.7 
 03C-2009 G15 M638655 Diagnosis/pretreatment 35 
 
2.77 116.98 
 
5.3 
 03C-2009 H04 PP Relapse  
 
41.32 1.23 99.87 1 37.3 
 03C-2009 H07 6382107 Relapse  
 
   
2 
  03E-2009 E05 6382107 Relapse  
 
21.83 0.16 74.85 2 67 
 03E-2009 E08 6454531 1st relapse (2 previous Rx) 
 
66.53 0.99 73.24 1 29 
 03C-2009 H10 F721798 1st relapse 
 
50.51 15.37 81.44 1 44 yes 
03C-2009 H13 F721798 Diagnosis/pretreatment 14 36.76 5.41 94.88 1 29 yes 
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TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03F-2009 A01 F721798 Not known  
 
36.8 0.32 65.19 
 
24.5 yes 
03D-2009 A07 6095348 Diagnosis/pretreatment 23 2.4 1.23 88.43 
 
21 
 03D-2009 A04 F605183 Relapse  15 32.57 114.86 109.32 
   03D-2009 A01 M619107 Relapse  
 
0.48 1.92 64.48 neg 10 
 03D-2009 A10 F600214 Not known 
 
69.25 2.7 107.17 neg 16.7 
 03D-2009 A14 M529089 Diagnosis/pretreatment 14 
   
neg 
  03D-2009 B02 M529089 1st relapse 
 
19.79 53.33 94.01 neg 40 yes 
03D-2009 B05 M549401 Relapse  
 
4.99 7.25 97.08 1 11.7 
 03D-2009 B09 M549401 Relapse  
 
1.44 5.34 38.93 neg 1 
 03D-2009 B12 M584317 Relapse (n=2 or 3) 
 
73.19 35.57 101.56 1 41 yes 
03D-2009 B15 6311123 Relapse  
 
52.04 80.56 80.41 2 47.7 
 03D-2009 C03 PP Not known 
 
0.36 0.38 10.34 1 24.7 
 03D-2009 C06 6003144 1st Relapse  
 
72.79 8.41 115.15 2 21.7 
 03D-2009 C09 44599HA 1st relapse 
 
61.93 14.82 92.07 2 67.3 
 03D-2009 C12 44599HA 1st relapse 
 
70.06 4.83 35.68 2 67.3 
 03E-2009 A01 F853428 1st relapse 
 
  
15.74 1 13.3 
 03D-2009 C15 F686876 1st relapse 
 
1.23 0.19 7.92 1 51.7 
 03D-2009 D03 F686876 2nd relapse 
 
28.41 82.1 78.20 1 40 
 03D-2009 D06 M721728 Not known  
 
66.18 43.28 93.02 
 
10.3 
 03D-2009 D10 6382378 Relapse  
 
9.57 0.43 59.03 2 13 
 03D-2009 D13 M596357 Relapse  
 
66.29 45.05 85.46 1 15 
 03D-2009 E07 M718147 Diagnosis/pretreatment 33 66.42 49.35 111.00 2 24.3 
 03D-2009 E10 M721068 1st relapse 
 
82.09 67.24 102.44 
 
20.3 
 03F-2009 B08 6386925 Relapse  
 
20.84 0.76 22.62 1 26 
 03D-2009 E13 M532973 Diagnosis/pretreatment 16 59.33 42.75 88.15 1 10.3 
 03D-2009 F01 1018763WH Not known 
 
45.04 14.61 109.43 1 17 
 03D-2009 F04 6105456 Relapse  
 
45.57 94.63 69.86 1 44.7 
 03D-2009 F07 6330509 Relapse  
 
      03D-2009 F10 6330509 Relapse  
 
15.17 3.39 65.40 2 18.7 
 03D-2009 F13 M715301 Not known 
 
   
2 
  03D-2009 G01 M715301 Not known 
 
11.76 14.8 70.03 neg 1 
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TMA SPOT HOSP.NO Biopsy at OS (mths) p110alpha p110beta p110delta PTEN Ki67 (%) Blastoid? 
03E-2009 E02 6330509 Relapse  
 
5.07 1.03 41.09 2 22.7 
 03F-2009 A08 M715301 2nd Relapse  
 
  
94.85 
   03D-2009 G04 M621647 Relapse  
 
5.45 62.13 74.87 neg 11.7 
 03D-2009 G08 M621647 Relapse  
 
45.15 55.93 95.78 1 10.3 
 03E-2009 B09 M700928  Not known 
 
      03D-2009 G11 M675633 Diagnosis/pretreatment  6 46.54 63.12 74.60 1 65.3 yes 
03E-2009 E14 6306724 2nd Relapse  
 
      03E-2009 G07 6306724 3rd Relapse 
 
67.6 4.9 82.88 
 
29 
 03E-2009 D07 6346692 3rd Relapse  
 
67.5 
 
74.85 
 
24.5 
 03E-2009 D14 6346692 4th relapse 
 
24.55 1.42 38.13 2 44.3 
 03F-2009 C04 6346692 3rd Relapse  
 
71.82 16.37 82.00 2 24.3 
 03E-2009 H01 9031243 Diagnosis/pretreatment 
 
61.88 
 
35.96 
 
25.5 
 03E-2009 H04 9031243 Primary refractory 
 
39.28 0.25 23.20 2 7.5 
 03D-2009 G14 M578752 Relapse  
 
  
0.20 1 
  03D-2009 H03 M578752 Relapse  
 
7.04 12.17 96.52 1 13 
 03D-2009 H06 M578752 Relapse  
 
6.53 6.05 98.63 1 22.3 
 03D-2009 H09 F590185 1st relapse 
 
66.24 3.56 64.46 neg 11 
 03D-2009 H12 M654123 Diagnosis/pretreatment 18 53.52 2.74 89.59 1 7.3 
 03D-2009 I03 M508453 Not known 
 
10.03 4.31 56.03 
 
6 
 03D-2009 I06 M508453 1st relapse 
 
15.07 26.15 87.07 
 
22.7 
 03D-2009 I09 6140686 Diagnosis/pretreatment 64 6.98 4.03 91.10 2 12.3 
 03E-2009 B03 M705674 Diagnosis/pretreatment 244* 
  
93.01 
   03E-2009 B06 M667385 Not known  
 
7.04 1.78 87.41 2 14.3 
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APPENDIX C 
 
Findings in NSG mice injected with MCL samples 2 and 3 
 
Figure A2. A) Clinical information and B) immunophenotypic characteristics of peripheral blood MCL 
sample 2. CD5 expression was weak or absent in the majority of CD20 positive cells. This was 
consistent with the lymph node histology from this patient which also demonstrated cells exhibiting 
blastoid morphology. C) There were no detectable MCL cells on peripheral blood flow cytometry at 
12 weeks on 4 NSG mice injected with sample 2. D) CD20 positive cells were not found on IHC of 
bone marrow from the femur. Representative image shown. E) No CD20 positive cells were found in 
NSG spleen as shown in the representative image. 
 
Figure A3. A) Clinical information and B) immunophenotypic characteristics of MCL sample 3. A high 
tumour cell content was found in this lymph node suspension prepared from this biopsy taken at 
second relapse. C) There were no detectable MCL cells on peripheral blood flow cytometry at 12 
weeks on 4 NSG mice injected with sample 2. D) CD20 positive cells were not found on IHC of bone 
marrow from the femur. Representative image shown. E) No CD20 positive cells were found in NSG 
spleen as shown in the representative image. 
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Figure A3 
A.
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D. E.
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